**Role of Fatty Acid Imaging with 123I- β-methyl-p-123I-Iodophenyl-Pentadecanoic Acid (123I-BMIPP) in Ischemic Heart Diseases**

Junichi Taki, Ichiro Matsunari, Hiroshi Wakabayashi, Anri Inaki and Seigo Kinuya

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53548

## **1. Introduction**

tors. Cell. (Journal Article; Research Support, N.I.H., Extramural; Research Support,

[39] Chen, J. X, Krane, M, Deutsch, M. A, Wang, L, Rav-acha, M, Gregoire, S, et al. Ineffi‐ cient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ Res. (Journal Article; Research Support, N.I.H., Extramural; Research Sup‐

[40] Mammoto, A, Connor, K. M, Mammoto, T, Yung, C. W, Huh, D, Aderman, C. M, et al. A mechanosensitive transcriptional mechanism that controls angiogenesis. Na‐ ture. (Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.). (2009). , 457(7233), 1103-8.

[41] KshitizHubbi ME, Ahn EH, Downey J, Afzal J, Kim DH, et al. Matrix rigidity controls endothelial differentiation and morphogenesis of cardiac precursors. Sci Signal. (Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S.

[42] Gnecchi, M, Danieli, P, & Cervio, E. Mesenchymal stem cell therapy for heart disease. Vascul Pharmacol. (Journal Article; Research Support, Non-U.S. Gov't). (2012). ,

[43] Noiseux, N, Gnecchi, M, Lopez-ilasaca, M, Zhang, L, Solomon, S. D, Deb, A, et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardi‐ um and improve cardiac function despite infrequent cellular fusion or differentia‐ tion. Mol Ther. (Journal Article; Research Support, N.I.H., Extramural; Research

[44] Mazhari, R, & Hare, J. M. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nat Clin Pract Cardiovasc Med. (Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-

[45] Lee, M. J, Kim, J, Kim, M. Y, Bae, Y. S, Ryu, S. H, Lee, T. G, et al. Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells. J Proteome Res. (Journal Article; Research Support, Non-

[46] Valadi, H, Ekstrom, K, Bossios, A, Sjostrand, M, Lee, J. J, & Lotvall, J. O. Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic ex‐ change between cells. Nat Cell Biol. (Journal Article; Research Support, Non-U.S.

[47] Alvarez-erviti, L, Seow, Y, Yin, H, Betts, C, Lakhal, S, & Wood, M. J. Delivery of siR‐ NA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol.

(Journal Article; Research Support, Non-U.S. Gov't). (2011). , 29(4), 341-5.

Non-U.S. Gov't). (2010). , 142(3), 375-86.

port, Non-U.S. Gov't). (2012). , 111(1), 50-5.

Support, Non-U.S. Gov't). (2006). , 14(6), 840-50.

U.S. Gov't). (2007). Suppl 1:S, 21-6.

U.S. Gov't). (2010). , 9(4), 1754-62.

Gov't). (2007). , 9(6), 654-9.

Gov't). (2012). a41.

57(1), 48-55.

174 Ischemic Heart Disease

In nuclear cardiology, myocardial perfusion imaging has been widely and thoroughly inves‐ tigated and used in various heart diseases, especially in ischemic heart diseases. However, beyond perfusion imaging, myocardial fatty acid metabolic imaging may yield valuable in‐ sight into the pathologic process of various heart diseases including ischemic heart diseases, cardiomyopathy, and diabetic heart etc [1, 2].

To run the contractile machinery and ion pumps to maintain rhythmic beating and integrity of the myocardium, the healthy heart derives its energy from a variety of oxidizable sub‐ strates such as fatty acids, glucose, lactate, amino acids etc. Approximately two-thirds or more of the total energy produced by myocardium is derived from fatty acid oxidation and the most of the remaining energy is covered by the glucose metabolism. Both fatty acid and glucose are catabolized to acetyl-COA through beta-oxidation and glycolysis and the metab‐ olite is oxidized in the tricarboxylic acid (TCA) cycle (Fig 1). To respond the constantly changing environmental conditions and energy demands, the heart maintains the balance between its energetic supply and demands by shifting fluxes through existing various meta‐ bolic pathways. Short-term modulation of substrate switching is based on an effective inter‐ play between various substrates, with metabolism of one substrate automatically suppressing the pathway of another substrate via rapid enzymatic changes. In the postpran‐ dial and under resting conditions, long-chain fatty acids are the predominant energy sub‐ strate for adult heart. On the other hand, during exercise or stress, predominant energy source shifts to carbohydrate [3] because the efficiency of glucose as substrate exceeds the

efficiency of fatty acids as substrate by as much as 40% [4]. In ischemia, oxidative metabo‐ lism of free fatty acid is decreased because β-oxidation of fatty acid in mitochondria requires a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycol‐ ysis that requires less oxygen consumption [5,6]. This metabolic switch from predominat fat‐ ty acid use to predominant glucose use seems crucial in preserving myocardial viability. (Fig 2) Therefore, different imaging tracers that permit direct assessment of myocardial me‐ tabolism are desired to evaluate the pathophysiological changes in various heart disease. Current available tracers for metabolic imaging are several fatty acid tracers, 18F-FDG for the evaluation of glucose metabolism, and 11C-acetate for the assessment of oxygen consump‐ tion. Of these tracers, only 123I-labeled fatty acid tracers are currently available for SPECT imaging. In this chapter, basic characteristics and clinical value of 123I-labeld fatty acid agents, especially β-methyl-p-123I-iodophenyl-pentadecanoic acid (BMIPP) follows.

**Figure 2.** Relation between myocardial perfusion and fatty acid and glucose metabolism.

viability will be lost eventually.

**2. Myocardial fatty acid metabolism**

When myocardial perfusion decreases, fatty acid metabolism can not be maintained be‐ cause β-oxidation of fatty acid in mitochondria requires a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycolysis that requires less oxygen consumption. Therefore, the decrease in tracer uptake for fatty acid substrate analogue such as BMIPP becomes more prominent than the decrease of perfusion tracer. On the contrary, anaerobic glucose metabolism relatively increases, presenting increased or pre‐ served FDG uptake in the area with reduced perfusion. When myocardial perfusion de‐ creases further, glucose anaerobic metabolism also declines finally and myocardial

Role of Fatty Acid Imaging with 123I- β-methyl-p-123I-Iodophenyl-Pentadecanoic Acid (123I-BMIPP)...

http://dx.doi.org/10.5772/53548

177

Although the primary sources of energy are lactate and glucose for fetal heart, fatty acids comprise 60% to 80% of the energy source in adult heart to run the contractile machinery

Due to hydrophobic nature of fatty acids, they are delivered to the heart by binding to plasma albumin or lipoproteins. After dissociating from albumin or lipoprotein, fatty acids can pass through the sarcolemmal membrane by diffusion or a facilitated transport mechanism. The fatty acid translocase CD36 was suggested that it accounts for the key

and ion pumps to maintain rhythmic beating and integrity of the myocardium [7].

**Figure 1.** Schematic presentation of substrates metabolism in myocardium. ADP = adenosine diphosphate, AMP = ad‐ enosine monophosphate, ATP = adenosine triphosphate, BMIPP = β-methyl-iodophenyl-pentadecanoic acid, CoA = coenzyme A, FFA = free fatty acid, PDH = pyruvate dehydrogenase, TCA = tricarboxylic acid, TG = triglyceride

**Figure 2.** Relation between myocardial perfusion and fatty acid and glucose metabolism.

When myocardial perfusion decreases, fatty acid metabolism can not be maintained be‐ cause β-oxidation of fatty acid in mitochondria requires a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycolysis that requires less oxygen consumption. Therefore, the decrease in tracer uptake for fatty acid substrate analogue such as BMIPP becomes more prominent than the decrease of perfusion tracer. On the contrary, anaerobic glucose metabolism relatively increases, presenting increased or pre‐ served FDG uptake in the area with reduced perfusion. When myocardial perfusion de‐ creases further, glucose anaerobic metabolism also declines finally and myocardial viability will be lost eventually.

## **2. Myocardial fatty acid metabolism**

efficiency of fatty acids as substrate by as much as 40% [4]. In ischemia, oxidative metabo‐ lism of free fatty acid is decreased because β-oxidation of fatty acid in mitochondria requires a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycol‐ ysis that requires less oxygen consumption [5,6]. This metabolic switch from predominat fat‐ ty acid use to predominant glucose use seems crucial in preserving myocardial viability. (Fig 2) Therefore, different imaging tracers that permit direct assessment of myocardial me‐ tabolism are desired to evaluate the pathophysiological changes in various heart disease. Current available tracers for metabolic imaging are several fatty acid tracers, 18F-FDG for the evaluation of glucose metabolism, and 11C-acetate for the assessment of oxygen consump‐ tion. Of these tracers, only 123I-labeled fatty acid tracers are currently available for SPECT imaging. In this chapter, basic characteristics and clinical value of 123I-labeld fatty acid

176 Ischemic Heart Disease

agents, especially β-methyl-p-123I-iodophenyl-pentadecanoic acid (BMIPP) follows.

**Figure 1.** Schematic presentation of substrates metabolism in myocardium. ADP = adenosine diphosphate, AMP = ad‐ enosine monophosphate, ATP = adenosine triphosphate, BMIPP = β-methyl-iodophenyl-pentadecanoic acid, CoA =

coenzyme A, FFA = free fatty acid, PDH = pyruvate dehydrogenase, TCA = tricarboxylic acid, TG = triglyceride

Although the primary sources of energy are lactate and glucose for fetal heart, fatty acids comprise 60% to 80% of the energy source in adult heart to run the contractile machinery and ion pumps to maintain rhythmic beating and integrity of the myocardium [7].

Due to hydrophobic nature of fatty acids, they are delivered to the heart by binding to plasma albumin or lipoproteins. After dissociating from albumin or lipoprotein, fatty acids can pass through the sarcolemmal membrane by diffusion or a facilitated transport mechanism. The fatty acid translocase CD36 was suggested that it accounts for the key uptake mechanism of long-chain fatty acid through the analysis of minority of patients with absent uptake of 123I-BMIPP (15-(p-iodophenyl)-3(R, S)-methylpentadecanoic acid) even without significant cardiac abnormality [8,9] The patients with deficient myocardial uptake of BMIPP has been proved to correspond to the patients with type I CD36 defi‐ ciency (neither platelets nor monocytes expresse CD36) [10-12] and biopsy specimen from the patients with absent myocardial BMIPP uptake and type I CD36 deficiency demon‐ strated no expression of CD36 on the myocardial capillary endothelial cells [13]. These pa‐ tients without BMIPP cardiac uptake showed compensatory increased FDG uptake [14,15] and several gene abnormalities related to CD36 deficiency have been reported [16,17]. Based on these clinical data and other animal experiments, it has been proved that CD36 plays a crucial role in fatty acid transport into the cells [18].

the image quality is excellent. Animal experiment demonstrated that the IPPA accumulated rapidly to myocardium followed by a two-component tracer clearance similar to 14C-palmi‐ tate, permitting estimation of metabolic rate [25]. The uptake of IPPA during exercise is re‐ lated to myocardial perfusion and its catabolism follows the usual metabolic pathway for βoxidation [26]. Through β-oxidation IPPA is metabolized to iodobenzoic acid and its metabolite iodohippurate, and these are rapidly excreted from the kidneys with the iodine still attached, resulting in high image quality with low background by preventing the build‐ up of free radioiodide [27]. Coronary occlusion and reperfusion blunted the uptake of IPPA and prolonged the clearance, but permanent coronary occlusion decreased the uptake signif‐ icantly and accelerated the clearance, indicating that the IPPA can be used to localize the area of myocardial ischemia and infarction [28]. However, still relatively fast rate of metabo‐ lism and clearance of IPPA precludes the clinical SPECT imaging, even in a rotating multidetector SPECT system. For initial IPPA uptake imaging, acquisition time should be shortened to prevent progressive undersampling due to rapid count decrease from the myo‐ cardium, resulting in the deterioration of image quality, and dynamic SPECT study may be necessary for kinetic analysis of β-oxidation. For this purpose, dynamic SPECT with cadmi‐ um zinc-telluride (CZT) multi-detector might be the choice of data acquisition and analysis

Role of Fatty Acid Imaging with 123I- β-methyl-p-123I-Iodophenyl-Pentadecanoic Acid (123I-BMIPP)...

http://dx.doi.org/10.5772/53548

179

**Figure 3.** Iodinated fatty acids analogues for SPECT. BMIPP = β-methyl-iodophenyl pentadecanoic acid, DMIPP = di‐ methyl-iodophenyl pentadecanoic acid, IHDA = 123I-heptadecanoic acid, IHXA =123I-hexadecanoic acid, IPPA = iodo‐

because of its high sensitivity [29].

phenyl pentadecanoic acid,

Once the fatty acid is taken up by the myocyte, it undergoes adenosine triphosphate (ATP) dependent conversion to acyl-CoAs and are consequently trapped inside the cell. Then the acyl-CoAs are taken up by mithochondria via an acyl carnitine carrier system and is rapidly catabolized by β-oxidation into 2-carbon fragments, acetyl-CoAs, which enter the TCA cycle for further oxidation to become water and carbon dioxide. (Fig 1) The half-life of β-oxidation is fast and in the order of minutes, but is dependent on the adequate oxygen availability. The remainder of the total fatty acid entering the myocyte is incorporated into the lipid pool, mainly in the form of triglycerides and phospholipids, or into myocardial structural lipids and presents in the myocardium for a long time. Turnover in the lipid pool is much slower with the half-life of the order of hours.

## **3. Tracers for fatty acid imaging for SPECT (Fig 3)**

In mid 1970's, several iodinated long chain fatty acids were developed by introducing ra‐ dioiodine to the terminal position of fatty acids without altering extraction efficiency com‐ pared with the natural compound [19-21]. These straight chain fatty acids, 123Ihexadecanoic acid (IHXA) and 123I -heptadecanoic acid (IHDA) were proved to be an indicator of myocardial perfusion in canine model and human [20,21]. After rapid initial myocardial extraction these traces showed biexponential clearance similar to that of 11Cpalmitate with rapid and slow components, those were thought to represent β-oxidation of fatty acids and fatty acids storage in lipid pool, respectively. However, a canine study suggested that washout rate of radioactivity from the heart reflected the back diffusion of deiodinated free iodine not by β-oxidation [20]. A clinical study with IHDA demonstrated high image quality early after injection but it deteriorated rapidly because of rapid reduc‐ tion of myocardial counts and increase in background counts by deiodinated radioiodine [23]. Accordingly, these characteristics of the tracers make IHDA and IHXA unattractive for clinical use, especially for SPECT study.

To overcome the problem of these alkyl fatty acids, the phenyl fatty acid was developed by attaching iodide to the para position of phenyl ring (IPPA) [24]. Because this agent demon‐ strates high myocardial uptake without essential release of free radioiodide into circulation, the image quality is excellent. Animal experiment demonstrated that the IPPA accumulated rapidly to myocardium followed by a two-component tracer clearance similar to 14C-palmi‐ tate, permitting estimation of metabolic rate [25]. The uptake of IPPA during exercise is re‐ lated to myocardial perfusion and its catabolism follows the usual metabolic pathway for βoxidation [26]. Through β-oxidation IPPA is metabolized to iodobenzoic acid and its metabolite iodohippurate, and these are rapidly excreted from the kidneys with the iodine still attached, resulting in high image quality with low background by preventing the build‐ up of free radioiodide [27]. Coronary occlusion and reperfusion blunted the uptake of IPPA and prolonged the clearance, but permanent coronary occlusion decreased the uptake signif‐ icantly and accelerated the clearance, indicating that the IPPA can be used to localize the area of myocardial ischemia and infarction [28]. However, still relatively fast rate of metabo‐ lism and clearance of IPPA precludes the clinical SPECT imaging, even in a rotating multidetector SPECT system. For initial IPPA uptake imaging, acquisition time should be shortened to prevent progressive undersampling due to rapid count decrease from the myo‐ cardium, resulting in the deterioration of image quality, and dynamic SPECT study may be necessary for kinetic analysis of β-oxidation. For this purpose, dynamic SPECT with cadmi‐ um zinc-telluride (CZT) multi-detector might be the choice of data acquisition and analysis because of its high sensitivity [29].

uptake mechanism of long-chain fatty acid through the analysis of minority of patients with absent uptake of 123I-BMIPP (15-(p-iodophenyl)-3(R, S)-methylpentadecanoic acid) even without significant cardiac abnormality [8,9] The patients with deficient myocardial uptake of BMIPP has been proved to correspond to the patients with type I CD36 defi‐ ciency (neither platelets nor monocytes expresse CD36) [10-12] and biopsy specimen from the patients with absent myocardial BMIPP uptake and type I CD36 deficiency demon‐ strated no expression of CD36 on the myocardial capillary endothelial cells [13]. These pa‐ tients without BMIPP cardiac uptake showed compensatory increased FDG uptake [14,15] and several gene abnormalities related to CD36 deficiency have been reported [16,17]. Based on these clinical data and other animal experiments, it has been proved that CD36

Once the fatty acid is taken up by the myocyte, it undergoes adenosine triphosphate (ATP) dependent conversion to acyl-CoAs and are consequently trapped inside the cell. Then the acyl-CoAs are taken up by mithochondria via an acyl carnitine carrier system and is rapidly catabolized by β-oxidation into 2-carbon fragments, acetyl-CoAs, which enter the TCA cycle for further oxidation to become water and carbon dioxide. (Fig 1) The half-life of β-oxidation is fast and in the order of minutes, but is dependent on the adequate oxygen availability. The remainder of the total fatty acid entering the myocyte is incorporated into the lipid pool, mainly in the form of triglycerides and phospholipids, or into myocardial structural lipids and presents in the myocardium for a long time. Turnover in the lipid pool is much slower

In mid 1970's, several iodinated long chain fatty acids were developed by introducing ra‐ dioiodine to the terminal position of fatty acids without altering extraction efficiency com‐ pared with the natural compound [19-21]. These straight chain fatty acids, 123Ihexadecanoic acid (IHXA) and 123I -heptadecanoic acid (IHDA) were proved to be an indicator of myocardial perfusion in canine model and human [20,21]. After rapid initial myocardial extraction these traces showed biexponential clearance similar to that of 11Cpalmitate with rapid and slow components, those were thought to represent β-oxidation of fatty acids and fatty acids storage in lipid pool, respectively. However, a canine study suggested that washout rate of radioactivity from the heart reflected the back diffusion of deiodinated free iodine not by β-oxidation [20]. A clinical study with IHDA demonstrated high image quality early after injection but it deteriorated rapidly because of rapid reduc‐ tion of myocardial counts and increase in background counts by deiodinated radioiodine [23]. Accordingly, these characteristics of the tracers make IHDA and IHXA unattractive

To overcome the problem of these alkyl fatty acids, the phenyl fatty acid was developed by attaching iodide to the para position of phenyl ring (IPPA) [24]. Because this agent demon‐ strates high myocardial uptake without essential release of free radioiodide into circulation,

plays a crucial role in fatty acid transport into the cells [18].

**3. Tracers for fatty acid imaging for SPECT (Fig 3)**

with the half-life of the order of hours.

178 Ischemic Heart Disease

for clinical use, especially for SPECT study.

$$\text{H}^{2\text{5}}\text{I}\text{---}(\text{CH}\_{2})\_{1\text{5}}\text{---}\text{COOH}\qquad\text{II}\text{---}\text{HXA}$$

$$\text{H}^{123}\text{I}-\text{(CH}\_{2}\text{)}\_{16}\text{---}\text{COOH} \tag{\text{H}\text{H}}\text{A} \tag{\text{H}\text{H}}\text{A}$$

$$\begin{array}{cccc} \text{H}^{123}\text{I}-\text{}\text{CH}-\text{(CH}\_{2}\text{)}\_{12}\text{I}-\text{CH}-\text{CH}\_{2}\text{---}\text{COOH} & \text{BMIP} \\\\ \text{H}^{123}\text{I}-\text{(CH}\_{2}\text{)}\_{12}\text{I}-\text{CH}-\text{CH}\_{2}\text{---}\text{COOH} & \text{DMIP} \\\\ \text{CH}\_{3}\text{I} & \text{CH}\_{3} \end{array}$$

**Figure 3.** Iodinated fatty acids analogues for SPECT. BMIPP = β-methyl-iodophenyl pentadecanoic acid, DMIPP = di‐ methyl-iodophenyl pentadecanoic acid, IHDA = 123I-heptadecanoic acid, IHXA =123I-hexadecanoic acid, IPPA = iodo‐ phenyl pentadecanoic acid,

Accordingly, a new fatty acid tracer with more prolonged cardiac retention has been devel‐ oped to improve quantitative image quality. For this purpose methyl branching was intro‐ duced at β-carbon position to slow myocardial clearance by inhibiting β-oxidation. Tow forms of iodine labeled modified fatty acids, 15-(p-iodophenyl)3-R, S-methylpentadecanoic acid (BMIPP) and 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP), has been de‐ veloped [30,31]. In fasted rats, myocardial half-time of BMIPP and DMIPP are far longer, at 30-45 min and 6-7 hr, respectively, than that of IPPA (5-10 min) [31]. In human, DMIPP showed higher liver uptake than that of BMIPP (heart/liver ratio was 0.39 ± 0.05 and 1.00 ± 0.12, respectively: p<0.001), suggesting that BMIPP is more favorable cardiac SPECT agent [32]. Especially in Japan and some European countries, BMIPP has since been widely stud‐ ied to investigate the clinical significance and basic properties. In Japan, 123I-BMIPP has been used in daily clinical practice for nearly 2 decades since 1993.

BMIPP and thallium uptake, whereas conventional BMIPP images at 30 min demonstrat‐ ed the discordant BMIPP uptake less than thallium [38]. These findings suggest that, in is‐ chemic myocardium, initial myocardial distribution of BMIPP may represent blood flow, followed by back diffusion of free BMIPP which is not incorporated into triglyceride pool after conversion to BMIPP-CoA, resulting in discordant BMIPP uptake less than thallium

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

181

In the first step of the common pathway of fatty acid metabolism, BMIPP also underwent ATP dependent conversion to BMIPP-CoA. Once BMIPP-CoA is synthesized, it is hardly back-diffused out of the cell and is retained within it [39,40]. Therefore, BMIPP myocardial retention may relate to the ATP level of the cells. Both in mouse myocardium treated with an electron transport uncoupler, dinitrophenol, which reduced intracellular ATP level with‐ out affecting acyl-CoA synthetase activity or CoA level, and in acutely damaged canine my‐ ocardium by coronary occlusion and reperfusion, BMIPP uptake was found to correlate with the tissue ATP levels [41,42]. Therefore, myocardial BMIPP uptake most likely reflects activation of BMIPP by CoA and indirectly reflects cellular ATP production resulting from

During acute phase of ischemia, reduced availability of oxygen suppresses β-oxidation and increases the proportion of fatty acid in the triglyceride pool. At this moment BMIPP may enter into this enlarged triglyceride pool. Accordingly, BMIPP uptake may possibly be in‐ creased in acute ischemia. Canine experiments with occlusion and reperfusion model showed higher BMIPP uptake than thallium (reverse mismatch) which is an opposite find‐ ing observed in clinical studies [43,44]. However, BMIPP uptake may change as a function of time after ischemia. A rat study with 20 min coronary occlusion and reperfusion demon‐ strated higher BMIPP uptake than thallium at 1 day after reperfusion but showed similar to or lower than thallium uptake at 5 day after reperfusion [45]. Another rat study with 20 min coronary occlusion and reperfusion revealed that increased BMIPP uptake in area at risk at 20 min and 1 day after reperfusion, followed by reduction of uptake at 3 to 7 days, though, recovered to normal level at 30 days after reperfusion [46]. By contrast, thallium uptake did not change throughout the 30 days observation period. As a result, higher BMIPP uptake than thallium in acute phase was inverted in subacute phase (discordant or mismatch BMIPP uptake less than thallium) and recovered to the similar uptake to that of thallium. After a transient ischemic insult, recovery of myocardial perfusion, metabolism and function may be temporally different. Although, delayed recovery of function after transient ische‐ mia is well documented in the experimental and clinical setting as stunned myocardium, de‐ layed recovery of regional metabolism or *metabolic stunning* which provide imprint prior ischemic event has been recognized recently. This delayed recovery of metabolism after quick recovery of perfusion provides a concept of *ischemic memory* imaging [47-50]. Thus BMIPP imaging during or after an episode of myocardial ischemia might provide crucial in‐

sights into pathophysiology of coronary artery disease over perfusion imaging.

on static images obtained 20-30 min after BMIPP injection.

fatty acid metabolism.

## **4. Myocardial kinetic of 123I-BMIPP (Fig 4)**

After intravenous injection of 123I-BMIPP, the tracer is delivered to myocardium depending on the regional flow and transported into myocardial cells via fatty acid translocase/CD36 involvement [10,11,13,16-18]. Once BMIPP is taken up by the myocyte, it will either backdiffuse to the plasma, accumulate in the lipid pool or undergo limited alpha and beta oxida‐ tion. Most of the BMIPP in the cytoplasm undergoes ATP dependent conversion to BMIPP-CoA and incorporated into triglyceride pool [31,33]. Canine study demonstrated that high first pass extraction (74%) within 30 sec of intracoronary BMIPP infusion, followed by a small fraction of washout (8.7% of infused BMIPP) for the next 30 min [34]. The washed out radioactiviy consist of backdiffused BMIPP (24% of all washed out radioactivity), α oxida‐ tion metabolite (27%), intermediate metabolites (33%), and full metabolite (16%), suggesting only small amount of BMIPP-CoA transported into mitochondria is metabolized by α oxida‐ tion (because first β oxidation is blocked by β-methyl branching), followed by β oxidation. The high uptake and low washout of the tracer indicates that BMIPP can be substantially considered as a metabolically trapped tracer like FDG.

Thirty minutes coronary occlusion and reperfusion was found to increase early back dif‐ fusion of nonmetabolized BMIPP from 25.1% to 34.7%, and in mild ischemia with 10 mi‐ nutes occlusion, back diffusion of BMIPP was closely correlated with lactate production (marker of ischemic severity) [35]. Pharmacological intervention with etomoxir, one of the carnitine palmotoyltransferase I inhibitor that inhibits the transport of long chain lipids into the mitochondria, enhanced early washout of radioactivity until 8 minutes after injec‐ tion due to increased back diffusion of BMIPP [36]. Dynamic SPECT in patients with coro‐ nary artery disease demonstrated that the BMIPP washout was observed early after BMIPP injection (2-6 min after injection) in the segments with stress induced thallium de‐ fects but not in the segments with normal thallium uptake and fixed thallium defects [37]. In patients with acute coronary syndrome, early dynamic BMIPP SPECT showed similar BMIPP and thallium uptake, whereas conventional BMIPP images at 30 min demonstrat‐ ed the discordant BMIPP uptake less than thallium [38]. These findings suggest that, in is‐ chemic myocardium, initial myocardial distribution of BMIPP may represent blood flow, followed by back diffusion of free BMIPP which is not incorporated into triglyceride pool after conversion to BMIPP-CoA, resulting in discordant BMIPP uptake less than thallium on static images obtained 20-30 min after BMIPP injection.

Accordingly, a new fatty acid tracer with more prolonged cardiac retention has been devel‐ oped to improve quantitative image quality. For this purpose methyl branching was intro‐ duced at β-carbon position to slow myocardial clearance by inhibiting β-oxidation. Tow forms of iodine labeled modified fatty acids, 15-(p-iodophenyl)3-R, S-methylpentadecanoic acid (BMIPP) and 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP), has been de‐ veloped [30,31]. In fasted rats, myocardial half-time of BMIPP and DMIPP are far longer, at 30-45 min and 6-7 hr, respectively, than that of IPPA (5-10 min) [31]. In human, DMIPP showed higher liver uptake than that of BMIPP (heart/liver ratio was 0.39 ± 0.05 and 1.00 ± 0.12, respectively: p<0.001), suggesting that BMIPP is more favorable cardiac SPECT agent [32]. Especially in Japan and some European countries, BMIPP has since been widely stud‐ ied to investigate the clinical significance and basic properties. In Japan, 123I-BMIPP has been

After intravenous injection of 123I-BMIPP, the tracer is delivered to myocardium depending on the regional flow and transported into myocardial cells via fatty acid translocase/CD36 involvement [10,11,13,16-18]. Once BMIPP is taken up by the myocyte, it will either backdiffuse to the plasma, accumulate in the lipid pool or undergo limited alpha and beta oxida‐ tion. Most of the BMIPP in the cytoplasm undergoes ATP dependent conversion to BMIPP-CoA and incorporated into triglyceride pool [31,33]. Canine study demonstrated that high first pass extraction (74%) within 30 sec of intracoronary BMIPP infusion, followed by a small fraction of washout (8.7% of infused BMIPP) for the next 30 min [34]. The washed out radioactiviy consist of backdiffused BMIPP (24% of all washed out radioactivity), α oxida‐ tion metabolite (27%), intermediate metabolites (33%), and full metabolite (16%), suggesting only small amount of BMIPP-CoA transported into mitochondria is metabolized by α oxida‐ tion (because first β oxidation is blocked by β-methyl branching), followed by β oxidation. The high uptake and low washout of the tracer indicates that BMIPP can be substantially

Thirty minutes coronary occlusion and reperfusion was found to increase early back dif‐ fusion of nonmetabolized BMIPP from 25.1% to 34.7%, and in mild ischemia with 10 mi‐ nutes occlusion, back diffusion of BMIPP was closely correlated with lactate production (marker of ischemic severity) [35]. Pharmacological intervention with etomoxir, one of the carnitine palmotoyltransferase I inhibitor that inhibits the transport of long chain lipids into the mitochondria, enhanced early washout of radioactivity until 8 minutes after injec‐ tion due to increased back diffusion of BMIPP [36]. Dynamic SPECT in patients with coro‐ nary artery disease demonstrated that the BMIPP washout was observed early after BMIPP injection (2-6 min after injection) in the segments with stress induced thallium de‐ fects but not in the segments with normal thallium uptake and fixed thallium defects [37]. In patients with acute coronary syndrome, early dynamic BMIPP SPECT showed similar

used in daily clinical practice for nearly 2 decades since 1993.

**4. Myocardial kinetic of 123I-BMIPP (Fig 4)**

180 Ischemic Heart Disease

considered as a metabolically trapped tracer like FDG.

In the first step of the common pathway of fatty acid metabolism, BMIPP also underwent ATP dependent conversion to BMIPP-CoA. Once BMIPP-CoA is synthesized, it is hardly back-diffused out of the cell and is retained within it [39,40]. Therefore, BMIPP myocardial retention may relate to the ATP level of the cells. Both in mouse myocardium treated with an electron transport uncoupler, dinitrophenol, which reduced intracellular ATP level with‐ out affecting acyl-CoA synthetase activity or CoA level, and in acutely damaged canine my‐ ocardium by coronary occlusion and reperfusion, BMIPP uptake was found to correlate with the tissue ATP levels [41,42]. Therefore, myocardial BMIPP uptake most likely reflects activation of BMIPP by CoA and indirectly reflects cellular ATP production resulting from fatty acid metabolism.

During acute phase of ischemia, reduced availability of oxygen suppresses β-oxidation and increases the proportion of fatty acid in the triglyceride pool. At this moment BMIPP may enter into this enlarged triglyceride pool. Accordingly, BMIPP uptake may possibly be in‐ creased in acute ischemia. Canine experiments with occlusion and reperfusion model showed higher BMIPP uptake than thallium (reverse mismatch) which is an opposite find‐ ing observed in clinical studies [43,44]. However, BMIPP uptake may change as a function of time after ischemia. A rat study with 20 min coronary occlusion and reperfusion demon‐ strated higher BMIPP uptake than thallium at 1 day after reperfusion but showed similar to or lower than thallium uptake at 5 day after reperfusion [45]. Another rat study with 20 min coronary occlusion and reperfusion revealed that increased BMIPP uptake in area at risk at 20 min and 1 day after reperfusion, followed by reduction of uptake at 3 to 7 days, though, recovered to normal level at 30 days after reperfusion [46]. By contrast, thallium uptake did not change throughout the 30 days observation period. As a result, higher BMIPP uptake than thallium in acute phase was inverted in subacute phase (discordant or mismatch BMIPP uptake less than thallium) and recovered to the similar uptake to that of thallium. After a transient ischemic insult, recovery of myocardial perfusion, metabolism and function may be temporally different. Although, delayed recovery of function after transient ische‐ mia is well documented in the experimental and clinical setting as stunned myocardium, de‐ layed recovery of regional metabolism or *metabolic stunning* which provide imprint prior ischemic event has been recognized recently. This delayed recovery of metabolism after quick recovery of perfusion provides a concept of *ischemic memory* imaging [47-50]. Thus BMIPP imaging during or after an episode of myocardial ischemia might provide crucial in‐ sights into pathophysiology of coronary artery disease over perfusion imaging.

procedures. Accordingly, the finding of mismatched BMIPP uptake less than perfusion tracers may be a predictor of functional recovery in acute myocardial infarction. For the evaluation of area at risk in acute myocardial infarction, BMIPP imaging in subacute phase is valuable. BMIPP defect size in subacute phase of myocardial infarction correlat‐ ed well with the risk area revealed by contrast ventriculography or echocardiography [47,60], and the area with BMIPP reduction 1 week after the onset of myocardial infarc‐ tion corresponded well to the area with perfusion defect which was demonstrated before revascularization therapy at admission [61]. These observations holds the concept of "*is‐ chemic memory imaging*" because BMIPP imaging obtained in subacute phase of myocar‐ dial infarction reflects prior ischemic damage or metabolically stunned myocardium even after the restoration of perfusion abnormality [47-49]. Therefore, BMIPP imaging may contribute to improving the detection of culprit lesion of the small amount of acute myo‐ cardial infarction. In patients with non ST elevated and non serum creatinine kinase-MB elevated but increased cTnT level, BMIPP SPECT at subacute phase can detect culprit

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

183

Mismatched uptake of BMIPP less than thallium is not also an uncommon finding in chronic phase of myocardial infarction. In 26 patients with prior myocardial infarction (>4 week af‐ ter onset) without revascularization therapy, resting BMIPP and exercise-redistribution thal‐ lium scintigraphies were studied. Sixty-seven % of the segments with discordant BMIPP uptake less than redistribution thallium showed reversible thallium defects, 21% showed fixed thallium defects and 12% showed normal thallium uptake, indicating that the myocar‐ dium with discordant BMIPP uptake less than redistribution thallium uptake were mostly exposed to stress induced ischemia [37]. In subacute to chronic phase of infraction (>2 week after onset), similar findings were reported, with most of the mismatched segments (22/27)

Because oxygen extraction by the myocardium is nearly complete, reduction of coronary flow against the myocardial oxygen demand evoke the metabolic switch from fatty acid oxidation to anaerobic glucose metabolism. Thus the BMIPP uptake might be suppressed in ischemia. In a study of 111 consecutive patients with acute chest pain without myo‐ cardial infarction, BMIPP SPECT at 2 days after the onset of chest pain showed regional abnormality in 74% of coronary abnormalities, while only 38% showed perfusion abnor‐ mality demonstrated by tetrofosmin within 24 hr after the onset of chest pain [64]. Re‐ cently, multicenter trial to evaluate the performance of BMIPP to detect acute coronary syndromes in emergency department patients with chest pain was conducted in a total of 507 patients without history of prior myocardial infarction [65]. BMIPP imaging was performed within 30 hours of symptom cessation. Sensitivity of detecting acute coronary syndrome increased from 43% in clinical diagnosis to 73% in BMIPP imaging alone. Both negative and positive predictive values of a clinical diagnosis alone increased significant‐ ly when combined BMIPP imaging from 62% to 83% and 41% to 58%, respectively.

coronary lesions more sensitively than thallium [62].

is associated with reversible thallium defect [63].

**5.2. Acute coronary syndrome and unstable angina pectoris**

**Figure 4.** Schematic presentation of 123I-BMIPP metabolism in myocardium. Abbreviations: see Figure 1.

## **5. 123I-BMIPP imaging in ischemic heart diseases**

#### **5.1. Acute myocardial infarction**

Discrepant BMIPP uptake less than thallium has been reported initially in 17 out of 28 patients with acute myocardial infarction. Such discordant BMIPP uptake was observed more often in areas of acute than chronic phase of myocardial infarction (59% at <4 week versus 31% at >4 week after onset), and more often in areas supplied with revascular‐ ized than non-revascularized arteries (74% versus 28%, respectively). In addition, region‐ al wall motion was more severely impaired in such perfusion-metabolic mismatching area [51]. In patients with acute myocardial infarction, BMIPP and 99mTc-MIBI SPECT at 4 to 10 days after thrombolysis demonstrated that the segments with more reduced BMIPP uptake than MIBI uptake (mismatching) showed either normal wall motion or demon‐ strated inotropic reserve during dobutamine stimulation [52]. In addition, several studies had demonstrated that areas of discordant BMIPP uptake less than perfusion tracers in acute or subacute stages of myocardial infarction showed improvement of wall motion abnormality on the subsequent follow-up periods [47,53-59]. These findings suggested that mismatch or discordant BMIPP uptake less than perfusion is indicative of jeopar‐ dized but viable myocardium and may correspond to stunned myocardium where func‐ tional abnormality is prolonged in association with sustained metabolic abnormalities (metabolically stunned myocardium) after perfusion recovery by successful reperfusion procedures. Accordingly, the finding of mismatched BMIPP uptake less than perfusion tracers may be a predictor of functional recovery in acute myocardial infarction. For the evaluation of area at risk in acute myocardial infarction, BMIPP imaging in subacute phase is valuable. BMIPP defect size in subacute phase of myocardial infarction correlat‐ ed well with the risk area revealed by contrast ventriculography or echocardiography [47,60], and the area with BMIPP reduction 1 week after the onset of myocardial infarc‐ tion corresponded well to the area with perfusion defect which was demonstrated before revascularization therapy at admission [61]. These observations holds the concept of "*is‐ chemic memory imaging*" because BMIPP imaging obtained in subacute phase of myocar‐ dial infarction reflects prior ischemic damage or metabolically stunned myocardium even after the restoration of perfusion abnormality [47-49]. Therefore, BMIPP imaging may contribute to improving the detection of culprit lesion of the small amount of acute myo‐ cardial infarction. In patients with non ST elevated and non serum creatinine kinase-MB elevated but increased cTnT level, BMIPP SPECT at subacute phase can detect culprit coronary lesions more sensitively than thallium [62].

Mismatched uptake of BMIPP less than thallium is not also an uncommon finding in chronic phase of myocardial infarction. In 26 patients with prior myocardial infarction (>4 week af‐ ter onset) without revascularization therapy, resting BMIPP and exercise-redistribution thal‐ lium scintigraphies were studied. Sixty-seven % of the segments with discordant BMIPP uptake less than redistribution thallium showed reversible thallium defects, 21% showed fixed thallium defects and 12% showed normal thallium uptake, indicating that the myocar‐ dium with discordant BMIPP uptake less than redistribution thallium uptake were mostly exposed to stress induced ischemia [37]. In subacute to chronic phase of infraction (>2 week after onset), similar findings were reported, with most of the mismatched segments (22/27) is associated with reversible thallium defect [63].

#### **5.2. Acute coronary syndrome and unstable angina pectoris**

**Figure 4.** Schematic presentation of 123I-BMIPP metabolism in myocardium. Abbreviations: see Figure 1.

Discrepant BMIPP uptake less than thallium has been reported initially in 17 out of 28 patients with acute myocardial infarction. Such discordant BMIPP uptake was observed more often in areas of acute than chronic phase of myocardial infarction (59% at <4 week versus 31% at >4 week after onset), and more often in areas supplied with revascular‐ ized than non-revascularized arteries (74% versus 28%, respectively). In addition, region‐ al wall motion was more severely impaired in such perfusion-metabolic mismatching area [51]. In patients with acute myocardial infarction, BMIPP and 99mTc-MIBI SPECT at 4 to 10 days after thrombolysis demonstrated that the segments with more reduced BMIPP uptake than MIBI uptake (mismatching) showed either normal wall motion or demon‐ strated inotropic reserve during dobutamine stimulation [52]. In addition, several studies had demonstrated that areas of discordant BMIPP uptake less than perfusion tracers in acute or subacute stages of myocardial infarction showed improvement of wall motion abnormality on the subsequent follow-up periods [47,53-59]. These findings suggested that mismatch or discordant BMIPP uptake less than perfusion is indicative of jeopar‐ dized but viable myocardium and may correspond to stunned myocardium where func‐ tional abnormality is prolonged in association with sustained metabolic abnormalities (metabolically stunned myocardium) after perfusion recovery by successful reperfusion

**5. 123I-BMIPP imaging in ischemic heart diseases**

**5.1. Acute myocardial infarction**

182 Ischemic Heart Disease

Because oxygen extraction by the myocardium is nearly complete, reduction of coronary flow against the myocardial oxygen demand evoke the metabolic switch from fatty acid oxidation to anaerobic glucose metabolism. Thus the BMIPP uptake might be suppressed in ischemia. In a study of 111 consecutive patients with acute chest pain without myo‐ cardial infarction, BMIPP SPECT at 2 days after the onset of chest pain showed regional abnormality in 74% of coronary abnormalities, while only 38% showed perfusion abnor‐ mality demonstrated by tetrofosmin within 24 hr after the onset of chest pain [64]. Re‐ cently, multicenter trial to evaluate the performance of BMIPP to detect acute coronary syndromes in emergency department patients with chest pain was conducted in a total of 507 patients without history of prior myocardial infarction [65]. BMIPP imaging was performed within 30 hours of symptom cessation. Sensitivity of detecting acute coronary syndrome increased from 43% in clinical diagnosis to 73% in BMIPP imaging alone. Both negative and positive predictive values of a clinical diagnosis alone increased significant‐ ly when combined BMIPP imaging from 62% to 83% and 41% to 58%, respectively. These findings indicates that BMIPP imaging can detect prolonged metabolic abnormali‐ ty or stunning in patients with acute chest pain up to 2 days after cessation of symptom.

cordance was observed in 82% of the segments with no redistribution but new fill-in af‐ ter thallium reinjection [71]. In addition, such discordance was observed in only 19% of the segments with fixed defects. Previous studies with stress-redistribution-reinjection thallium demonstrated that the myocardium with new fill-in after thallium reinjection is characterized as severely ischemic but viable myocardium with frequent wall motion ab‐ normalities that may recover after revascularization [72,73]. Accordingly, these observa‐ tion may indicate that discordant BMIPP uptake less than thallium is suggestive of the

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

185

The concept of ischemic memory imaging of BMIPP has been tested in 32 patients with exer‐ cise-induced ischemia on thallium SPECT. BMIPP imaging at rest within 30 hrs of ischemia, which was induced and confirmed by exercise thallium SPECT, revealed reduction of BMIPP uptake corresponding to the ischemic area detected by stress thallium study in more than 90 % of patients [50]. Therefore, the authors concluded that BMIPP can identify sus‐ tained metabolic abnormality as a ischemic memory imaging at least until 30 hrs after stress induced ischemic episodes. This finding was complemented by the studies assessing glucose metabolism in patients undergoing exercise testing using FDG. Those have shown that a metabolic switch from fatty acid to glucose use occurs promptly when myocardial ischemia is induced during exercise and this metabolic switch to glucose may persist for 24hours, de‐

Accumulated data in patients with chronic ischemic heart disease in Japan, however, dem‐ onstrated that reduced BMIPP uptake was frequently observed independent of prior radio‐ nuclide and ECG stress tests but related to severe ischemia and wall motion abnormality, raise the possibility that BMIPP reduction reflects the substrate shift from fatty acid to glu‐ cose as a results of repeated myocardial ischemia rather than reflecting the single episode of metabolic stunning. Myocardium exposed to repetitive ischemia or stunning is subsequently adapted metabolically (metabolic remodeling) into chronic ischemic myocardium, so called hibernation [76-78]. In hibernating myocardium, energy substrate is shifted from fatty acid to glucose, contractility is impaired but with recruitable inotropic reserve, and myocardial flow reserve is severely impaired. In relation to this issue, relationship between BMIPP up‐ take and absolute myocardial blood flow by PET was investigated in patients with chronic stable angina without previous myocardial infarction. The results demonstrated that rest myocardial blood flow was preserved independent of BMIPP uptake. However, hyperemic myocardial blood flow was decreased in the area with reduced BMIPP uptake, resulting in the severity of impaired myocardial flow reserve correlated to the reduction of BMIPP up‐ take [79]. Thus, reduced BMIPP uptake implies impaired myocardial flow reserve and may reflects adaptive substrate shifts or metabolic remodeling in hibernating myocardium. Rep‐ resentative case with stable angina pectoris who underwent BMIPP and thallium SPECT be‐

myocardium jeopardized by more severe ischemia.

spite restoration of blood flow at rest [74,75].

fore and after coronary intervention (Fig 5).

In patients with unstable angina, discordant BMIPP uptake less than thallium has also been observed frequently [66-69]. In patients with unstable angina without prior myocar‐ dial infarction, comparison of BMIPP image and stress thallium scan performed after sta‐ bilization of their condition demonstrated that BMIPP decrease was associated with stress perfusion abnormality in 44 of 57 (77%) segments and degree of BMIPP reduction correlated with the degree of perfusion abnormality at stress, degree of wall motion ab‐ normality, and severity of coronary artery stenosis [66]. In another study in patients with unstable angina after medication and elimination of chest pain disclosed that patients with abnormal BMIPP uptake had more severe coronary artery stenosis and more collat‐ eral opacification than patients without BMIPP abnormality. In addition, revasculariza‐ tion was performed in 82% of patients with abnormal BMIPP images, while in only 22% of patients with normal BMIPP images, accordingly, BMIPP imaging may be helpful in decision-making regarding interventional treatment [68]. These findings indicate that re‐ duced BMIPP uptake in patients with unstable angina may represent persistent metabol‐ ic abnormality reflecting prior severe ischemia or repetitive ischemic insults, thus the concept of ischemic memory imaging could be extended and applied to these patients population. In other words, BMIPP imaging could extend time window for detecting pre‐ vious ischemic event after the resolution of perfusion abnormality.

#### **5.3. Chronic stable coronary artery disease**

In chronic stable coronary artery disease even without history of myocardial infarction, discordant BMIPP uptake less than perfusion tracer is also a common finding. Compari‐ son of BMIPP and stress-reinjection thallium SPECT in 45 patients with chronic coronary artery disease demonstrated that most of the segments (118/124) with discordant BMIPP uptake less than reinjection-thallium were associated with demand ischemia indicated by reversible thallium defects [70]. When reversible thallium defects were analyzed, approxi‐ mately half of the segments evidenced discordant BMIPP uptake less than reinjection thallium. On the other hand, around 80% of the segments with fixed thallium defects demonstrated concordant reduction of both tracers, suggesting myocardium with re‐ duced or poor viability has metabolic abnormality similar to the degree of resting perfu‐ sion abnormality. When reversible thallium defects were analyzed with respect to the evidence of discordant BMIPP uptake less than thallium and regional wall motion abnor‐ mality, wall motion was more severely impaired in the segments with discordant BMIPP uptake less than thallium than those without such discordance in both subset of patients with and without old myocardial infarction. However, severity of coronary artery steno‐ sis was similar in the vascular teritory with discordant BMIPP uptake less than reinjec‐ tion thallium and those without such discordance. Comparison of BMIPP and stressredistribution-reinjection thallium imaging in 55 patients with stable coronary artery disease revealed that discordant BMIPP uptake less than thallium was observed in only 37% of the segments with thallium redistribution after exercise, on the contrary, such dis‐ cordance was observed in 82% of the segments with no redistribution but new fill-in af‐ ter thallium reinjection [71]. In addition, such discordance was observed in only 19% of the segments with fixed defects. Previous studies with stress-redistribution-reinjection thallium demonstrated that the myocardium with new fill-in after thallium reinjection is characterized as severely ischemic but viable myocardium with frequent wall motion ab‐ normalities that may recover after revascularization [72,73]. Accordingly, these observa‐ tion may indicate that discordant BMIPP uptake less than thallium is suggestive of the myocardium jeopardized by more severe ischemia.

These findings indicates that BMIPP imaging can detect prolonged metabolic abnormali‐ ty or stunning in patients with acute chest pain up to 2 days after cessation of symptom.

In patients with unstable angina, discordant BMIPP uptake less than thallium has also been observed frequently [66-69]. In patients with unstable angina without prior myocar‐ dial infarction, comparison of BMIPP image and stress thallium scan performed after sta‐ bilization of their condition demonstrated that BMIPP decrease was associated with stress perfusion abnormality in 44 of 57 (77%) segments and degree of BMIPP reduction correlated with the degree of perfusion abnormality at stress, degree of wall motion ab‐ normality, and severity of coronary artery stenosis [66]. In another study in patients with unstable angina after medication and elimination of chest pain disclosed that patients with abnormal BMIPP uptake had more severe coronary artery stenosis and more collat‐ eral opacification than patients without BMIPP abnormality. In addition, revasculariza‐ tion was performed in 82% of patients with abnormal BMIPP images, while in only 22% of patients with normal BMIPP images, accordingly, BMIPP imaging may be helpful in decision-making regarding interventional treatment [68]. These findings indicate that re‐ duced BMIPP uptake in patients with unstable angina may represent persistent metabol‐ ic abnormality reflecting prior severe ischemia or repetitive ischemic insults, thus the concept of ischemic memory imaging could be extended and applied to these patients population. In other words, BMIPP imaging could extend time window for detecting pre‐

In chronic stable coronary artery disease even without history of myocardial infarction, discordant BMIPP uptake less than perfusion tracer is also a common finding. Compari‐ son of BMIPP and stress-reinjection thallium SPECT in 45 patients with chronic coronary artery disease demonstrated that most of the segments (118/124) with discordant BMIPP uptake less than reinjection-thallium were associated with demand ischemia indicated by reversible thallium defects [70]. When reversible thallium defects were analyzed, approxi‐ mately half of the segments evidenced discordant BMIPP uptake less than reinjection thallium. On the other hand, around 80% of the segments with fixed thallium defects demonstrated concordant reduction of both tracers, suggesting myocardium with re‐ duced or poor viability has metabolic abnormality similar to the degree of resting perfu‐ sion abnormality. When reversible thallium defects were analyzed with respect to the evidence of discordant BMIPP uptake less than thallium and regional wall motion abnor‐ mality, wall motion was more severely impaired in the segments with discordant BMIPP uptake less than thallium than those without such discordance in both subset of patients with and without old myocardial infarction. However, severity of coronary artery steno‐ sis was similar in the vascular teritory with discordant BMIPP uptake less than reinjec‐ tion thallium and those without such discordance. Comparison of BMIPP and stressredistribution-reinjection thallium imaging in 55 patients with stable coronary artery disease revealed that discordant BMIPP uptake less than thallium was observed in only 37% of the segments with thallium redistribution after exercise, on the contrary, such dis‐

vious ischemic event after the resolution of perfusion abnormality.

**5.3. Chronic stable coronary artery disease**

184 Ischemic Heart Disease

The concept of ischemic memory imaging of BMIPP has been tested in 32 patients with exer‐ cise-induced ischemia on thallium SPECT. BMIPP imaging at rest within 30 hrs of ischemia, which was induced and confirmed by exercise thallium SPECT, revealed reduction of BMIPP uptake corresponding to the ischemic area detected by stress thallium study in more than 90 % of patients [50]. Therefore, the authors concluded that BMIPP can identify sus‐ tained metabolic abnormality as a ischemic memory imaging at least until 30 hrs after stress induced ischemic episodes. This finding was complemented by the studies assessing glucose metabolism in patients undergoing exercise testing using FDG. Those have shown that a metabolic switch from fatty acid to glucose use occurs promptly when myocardial ischemia is induced during exercise and this metabolic switch to glucose may persist for 24hours, de‐ spite restoration of blood flow at rest [74,75].

Accumulated data in patients with chronic ischemic heart disease in Japan, however, dem‐ onstrated that reduced BMIPP uptake was frequently observed independent of prior radio‐ nuclide and ECG stress tests but related to severe ischemia and wall motion abnormality, raise the possibility that BMIPP reduction reflects the substrate shift from fatty acid to glu‐ cose as a results of repeated myocardial ischemia rather than reflecting the single episode of metabolic stunning. Myocardium exposed to repetitive ischemia or stunning is subsequently adapted metabolically (metabolic remodeling) into chronic ischemic myocardium, so called hibernation [76-78]. In hibernating myocardium, energy substrate is shifted from fatty acid to glucose, contractility is impaired but with recruitable inotropic reserve, and myocardial flow reserve is severely impaired. In relation to this issue, relationship between BMIPP up‐ take and absolute myocardial blood flow by PET was investigated in patients with chronic stable angina without previous myocardial infarction. The results demonstrated that rest myocardial blood flow was preserved independent of BMIPP uptake. However, hyperemic myocardial blood flow was decreased in the area with reduced BMIPP uptake, resulting in the severity of impaired myocardial flow reserve correlated to the reduction of BMIPP up‐ take [79]. Thus, reduced BMIPP uptake implies impaired myocardial flow reserve and may reflects adaptive substrate shifts or metabolic remodeling in hibernating myocardium. Rep‐ resentative case with stable angina pectoris who underwent BMIPP and thallium SPECT be‐ fore and after coronary intervention (Fig 5).

who are unable to perform adequate exercise testing or pharmacologic stress myocardial perfusion imaging, such as those presenting with acute chest pain and patients with end

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

187

Improvement of regional or global systolic function can be achieved if revascularization of viable myocardium is successfully performed. Therefore, assessment of residual myo‐ cardial viability in the setting of dysfunctional myocardium due to significant coronary artery disease is a key issue in making clinical decisions with respect to revascularization procedures. In this respect, stress myocardial perfusion SPECT has been extensively in‐ vestigated. The hallmarks of myocardial viability supplied by a stenosed or occluded cor‐ onary artery are the perfusion defect with thallium redistribution on stress-redistribution or rest-redistribution images, fill-in of thallium, setamibi, and tetrofosmin after reinjec‐ tion, or significant uptake on resting or reinjection images (usually more than 50-60% up‐ take of normal area). However, the ability of perfusion tracers to differentiate viable from non-viable myocardium is not completely satisfactory as evidenced by recent viabil‐ ity studies using perfusion tracers [82-84]. In terms of the hallmark of viability in BMIPP imaging, there are several substantial evidences that discordant BMIPP uptake less than perfusion tracers is a marker of viability; 1) as previously described, such mismatch is associated with ischemic myocardium as evidenced by stress perfusion studies, 2) in‐ creased FDG uptake was observed in areas with discordant BMIPP uptake less than thal‐ lium and higher oxidative metabolism by11C-acetate PET was observed in mismatched area than the area with concordant reduction of BMIPP and perfusion [85], 3) myocar‐ dial areas with BMIPP uptake less than sestamibi were more likely to have a positive re‐ sponse to dobutamine than areas with matched defect [86,87], 4) histologic examination in patients with bypass surgery demonstrated that BMIPP uptake reduction against % fibrosis looked biphasic, with steep reduction of BMIPP uptake within 20% of fibrosis, al‐ though, thallium uptake reduction correlated linearly to % fibrosis, implying the areas

with discordant BMIPP uptake less than thallium had less than 20% fibrosis [88].

Functional recovery after revascularization has been investigated in relation to BMIPP up‐ take abnormality in patients with chronic coronary artery disease. Discordant BMIPP uptake less than thallium could predict functional recovery after revascularization more precisely than exercise-reinjection thallium study. In addition, the extent of discordance were a good predictor of global ejection fraction improvement after revascularization [89]. Similarly, area with discordant BMIPP uptake less than sestamibi measured by quantitative analysis was highly predictive of improvement of ejection fraction, wall motion and free fatty acid utiliza‐ tion after revascularization [87]. Interestingly, the comparison of FDG, BMIPP, and sestami‐ bi uptake in patients with old myocardial infarction and stable ischemic regional wall motion abnormalities demonstrated that extent of discordant BMIPP uptake less than FDG uptake before revascularization highly correlated with ejection fraction improvement after revascularization (r = 0.74) and also the extent of discordant BMIPP uptake less than sesta‐ mibi correlated significantly with ejection fraction improvement (r = 0.50). However, no sig‐

**5.5. Myocardial viability assessment and prediction of functional recovery**

stage renal disease with hemodialysis.

**Figure 5.** Short axis and horizontal long axis slices of 201Tl, 123I- BMIPP and gated blood pool images. The patient with angina pectoris underwent thallium and BMIPP SPECT. Discordant BMIPP uptake less than thallium in antero-lateral wall was observed (arrows). Gated blood pool scintigraphy demonstrated mild hypokinesis in antero-lateral wall. Stroke volume image showed reduced stroke volume in anterolateral wall (arrow). Coronary angiography showed se‐ vere stenosis of the first diagonal brunch of the left anterior descending coronary artery. Coronary angioplasty was successfully performed and BMIPP uptake and wall motion abnormality improved 8 month later. The discordant BMIPP uptake less than thallium depicted the dysfunctional but viable myocardium or hibernating myocardium in an‐ terolateral wall. ED = end-diastolic, ES = end-systolic, PTCA = percutaneous transluminal coronary angioplasty, SV = stroke volume

#### **5.4. Detection of coronary artery disease**

Meta-analysis for the assessment of diagnostic accuracy of BMIPP imaging for the detection of coronary artery disease was conducted with 7 studies between 1995 and 2004 [80]. A total of 528 patients with a high prevalence of coronary artery disease who underwent both BMIPP imaging and coronary angiography were analyzed using a random-effects model. The overall sensitivity and specificity were 78% (95% confidence interval, 73% to 81%) and 84% (95% confidence interval, 77% to 89%). The summary receiver operating characteristic curve analysis showed that the area under the curve was 0.91 (SE, 0.020), and the Q\* index was 0.84 (SE, 0.022), indicating excellent diagnostic accuracy. This diagnostic performance is comparable with stress myocardial perfusion SPECT reported by meta-analysis; a sensitivity and specificity of 88% and 73%, respectively [81]. Thus, stress SPECT imaging is a more sen‐ sitive test, whereas BMIPP imaging is a more specific test. Unlike stress myocardial perfu‐ sion imaging, BMIPP imaging is obtained without the use of exercise or pharmacologic agents. Therefore, BMIPP imaging at rest may be an alternative imaging modality for those who are unable to perform adequate exercise testing or pharmacologic stress myocardial perfusion imaging, such as those presenting with acute chest pain and patients with end stage renal disease with hemodialysis.

#### **5.5. Myocardial viability assessment and prediction of functional recovery**

**Figure 5.** Short axis and horizontal long axis slices of 201Tl, 123I- BMIPP and gated blood pool images. The patient with angina pectoris underwent thallium and BMIPP SPECT. Discordant BMIPP uptake less than thallium in antero-lateral wall was observed (arrows). Gated blood pool scintigraphy demonstrated mild hypokinesis in antero-lateral wall. Stroke volume image showed reduced stroke volume in anterolateral wall (arrow). Coronary angiography showed se‐ vere stenosis of the first diagonal brunch of the left anterior descending coronary artery. Coronary angioplasty was successfully performed and BMIPP uptake and wall motion abnormality improved 8 month later. The discordant BMIPP uptake less than thallium depicted the dysfunctional but viable myocardium or hibernating myocardium in an‐ terolateral wall. ED = end-diastolic, ES = end-systolic, PTCA = percutaneous transluminal coronary angioplasty, SV =

Meta-analysis for the assessment of diagnostic accuracy of BMIPP imaging for the detection of coronary artery disease was conducted with 7 studies between 1995 and 2004 [80]. A total of 528 patients with a high prevalence of coronary artery disease who underwent both BMIPP imaging and coronary angiography were analyzed using a random-effects model. The overall sensitivity and specificity were 78% (95% confidence interval, 73% to 81%) and 84% (95% confidence interval, 77% to 89%). The summary receiver operating characteristic curve analysis showed that the area under the curve was 0.91 (SE, 0.020), and the Q\* index was 0.84 (SE, 0.022), indicating excellent diagnostic accuracy. This diagnostic performance is comparable with stress myocardial perfusion SPECT reported by meta-analysis; a sensitivity and specificity of 88% and 73%, respectively [81]. Thus, stress SPECT imaging is a more sen‐ sitive test, whereas BMIPP imaging is a more specific test. Unlike stress myocardial perfu‐ sion imaging, BMIPP imaging is obtained without the use of exercise or pharmacologic agents. Therefore, BMIPP imaging at rest may be an alternative imaging modality for those

stroke volume

186 Ischemic Heart Disease

**5.4. Detection of coronary artery disease**

Improvement of regional or global systolic function can be achieved if revascularization of viable myocardium is successfully performed. Therefore, assessment of residual myo‐ cardial viability in the setting of dysfunctional myocardium due to significant coronary artery disease is a key issue in making clinical decisions with respect to revascularization procedures. In this respect, stress myocardial perfusion SPECT has been extensively in‐ vestigated. The hallmarks of myocardial viability supplied by a stenosed or occluded cor‐ onary artery are the perfusion defect with thallium redistribution on stress-redistribution or rest-redistribution images, fill-in of thallium, setamibi, and tetrofosmin after reinjec‐ tion, or significant uptake on resting or reinjection images (usually more than 50-60% up‐ take of normal area). However, the ability of perfusion tracers to differentiate viable from non-viable myocardium is not completely satisfactory as evidenced by recent viabil‐ ity studies using perfusion tracers [82-84]. In terms of the hallmark of viability in BMIPP imaging, there are several substantial evidences that discordant BMIPP uptake less than perfusion tracers is a marker of viability; 1) as previously described, such mismatch is associated with ischemic myocardium as evidenced by stress perfusion studies, 2) in‐ creased FDG uptake was observed in areas with discordant BMIPP uptake less than thal‐ lium and higher oxidative metabolism by11C-acetate PET was observed in mismatched area than the area with concordant reduction of BMIPP and perfusion [85], 3) myocar‐ dial areas with BMIPP uptake less than sestamibi were more likely to have a positive re‐ sponse to dobutamine than areas with matched defect [86,87], 4) histologic examination in patients with bypass surgery demonstrated that BMIPP uptake reduction against % fibrosis looked biphasic, with steep reduction of BMIPP uptake within 20% of fibrosis, al‐ though, thallium uptake reduction correlated linearly to % fibrosis, implying the areas with discordant BMIPP uptake less than thallium had less than 20% fibrosis [88].

Functional recovery after revascularization has been investigated in relation to BMIPP up‐ take abnormality in patients with chronic coronary artery disease. Discordant BMIPP uptake less than thallium could predict functional recovery after revascularization more precisely than exercise-reinjection thallium study. In addition, the extent of discordance were a good predictor of global ejection fraction improvement after revascularization [89]. Similarly, area with discordant BMIPP uptake less than sestamibi measured by quantitative analysis was highly predictive of improvement of ejection fraction, wall motion and free fatty acid utiliza‐ tion after revascularization [87]. Interestingly, the comparison of FDG, BMIPP, and sestami‐ bi uptake in patients with old myocardial infarction and stable ischemic regional wall motion abnormalities demonstrated that extent of discordant BMIPP uptake less than FDG uptake before revascularization highly correlated with ejection fraction improvement after revascularization (r = 0.74) and also the extent of discordant BMIPP uptake less than sesta‐ mibi correlated significantly with ejection fraction improvement (r = 0.50). However, no sig‐ nificant correlation was observed between the area with discordant FDG uptake more than sestamib and ejection fraction recovery [90]. The results are quite intuitive because, in ische‐ mic and viable myocardium, substrate shift from fatty acid to glucose would take place, hence, mismatch of FDG and BMIPP uptake should be prominent but mismatch between BMIPP and sestamibi might be modest. These data suggest that discordant BMIPP uptake less than perfusion may represent reversible ischemic myocardial injury or hibernating my‐ ocardium and that the regional and global dysfunction will improve after revascularization in patients with chronic stable coronary artery disease. Metabolic stunning is also a good marker of functional recovery. In acute myocardial infarction with emergency revasculariza‐ tion, BMIPP and tetrofosmin mismatch around 1 week after the revascularization predicted recovery of ejection fraction and wall motion 3 month later [91,92].

years: 92% vs 80% (P = 0.0003), respectively). More importantly, BMIPP was able to select a high-risk subgroup among patients with diabetes mellitus as well as non-diabetic patients, with 41% event rate in diabetic patients with BMIPP defect score 5 or more but only 4%

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

189

One of the strength of BMIPP imaging in daily clinical use is its simplicity since it offers metabolic information without stress procedure. It is a matter of great interest whether rest‐ ing BMIPP imaging offers complementary or additional prognostic information to that pro‐ vided conventional stress perfusion imaging. One hundred and sity-seven consecutive patients with angina pectoris but without prior myocardial infarction who had undergone both BMIPP and stress thallium imaging were followed up for 48 months [99]. For overall cardiac events (5 hard and 29 soft events), multivariate Cox's analysis revealed that reduced BMIPP uptake, stress perfusion score, diabetes, and left ventricular ejection fraction were the significant predictors. No hard event was observed with normal BMIPP uptake, whereas 2 patients with nearly normal stress perfusion with impaired BMIPP uptake had a hard event. The authors concluded that resting BMIPP imaging may provide significant prognos‐

Recently meta-analysis on the prognostic value of BMIPP imaging in acute coronary syn‐ drome, acute myocardial infarction, and stable coronary artery disease was reported [100]. In 3 studies involving 541 patients with suspected acute coronary syndrome who were excluded for acute myocardial infarction, an abnormal finding on BMIPP imaging significantly associated with future hard cardiac events, defined as cardiac death and non-fatal myocardial infarction. The negative predictive value of BMIPP imaging for fu‐ ture hard and soft events were 98.9% and 92.3% over 3.5 years, respectively. In 6 studies which comprised 607 patients with acute myocardial infarction, larger defect on BMIPP imaging was significantly associated with cardiac death and hard events with relative risk of 2.81 and 3.87, respectively. Two studies included 166 patients with stable coro‐ nary artery disease who underwent elective revascularization. Both studies evaluated the prognostic value of mismatched BMIPP uptake less than perfusion, and showed contrast‐ ing results depending on the timing of BMIPP imaging to relative to revascularization. The presence of mismatched myocardium before revascularization, which suggested a jeopardized but viable myocardium, is associated with fewer events if patients undergo successful revascularization. However, the mismatch occurs after revascularization, indi‐

In chronic kidney disease (CKD), cardiovascular disease accounts for most of the morbid‐ ity and mortality in both pre-dialysis and after the onset of end stage renal disease. Stress myocardial perfusion imaging has become increasingly recognized as a powerful prognostic tool for cardiovascular outcomes in patents with known or suspected coro‐ nary artery disease. Abnormal stress myocardial perfusion scan is more common in pa‐ tients with CKD and stress perfusion imaging is confirmed as a powerful tool for predicting outcomes across entire spectrum of renal dysfunction. At the same time, pres‐

event rate in non-diabetic patients with BMIPP defect score lower than 5.

tic information independent of stress myocardial perfusion imaging.

cating residual ischemia, the more hard events occur.

**5.7. Chronic kidney disease**

#### **5.6. Risk stratification and prediction of the prognosis**

Assessment of prognostic value of BMIPP imaging over perfusion tracers in patients with coronary artery disease is a matter of clinical importance. The initial study for the assess‐ ment of prognostic implications of BMIPP imaging was conducted in 50 consecutive pa‐ tients with myocardial infarction with a mean follow up period of 23 months [93]. During the follow-up period, 9 patients had cardiac events; 8 of the 9 patients with cardiac events showed discordant BMIPP uptake less than reinjection thallium, whereas only 20 of 41 pa‐ tients without cardiac events showed such mismatch. When all the clinical and radionuclide variables were analyzed by Cox regression analysis, presence of discordant BMIPP uptake was the best, and an independent, predictor of future cardiac events followed by the num‐ ber of coronary artery stenosis. BMIPP and thallium imaging performed within 1 month of acute myocardial infarction demonstrated that impaired BMIPP uptake and mismatched BMIPP uptake less than thallium are related to a high probability of fatal and non-fatal car‐ diac events [94] and the defect score of BMIPP and mismatched BMIPP uptake less than thallium provided incremental predictive value for future cardiac events [95,96].

In the patients with chronic stage of myocardial infarction, clinical value of BMIPP imaging for predicting prognosis is also demonstrated. BMIPP imaging performed before revascula‐ rization in 76 patients with chronic stable ischemia (including 61 patients with myocardial infarction after at least 3 month of onset) with left ventricular dysfunction has been analyzed [97]. Patients with large amount of discordant BMIPP uptake less than thallium demonstrat‐ ed greater ejection fraction improvement after revascularization and, interestingly, showed significantly better event free survival than patients with small amount or no perfusion and metabolic mismatch. These data indicate that patients with significant amount of discordant BMIPP uptake less than thallium may benefit from revascularization.

In chronic coronary artery disease without old myocardial infarction, value of BMIPP imag‐ ing for risk stratification has been also demonstrated. In 270 patients, BMIPP defect score was analyzed with respect to cardiac event during a median follow-up of 3.9 years [98]. Ka‐ plan-Meier survival estimates revealed that patients with a summed BMIPP defect score lower than 5 showed a better prognosis than the patients with more defect of BMIPP (a hard event-free survival rate at 3 years: 98% vs 93% (P = 0.03), all event-free survival rate at 3 years: 92% vs 80% (P = 0.0003), respectively). More importantly, BMIPP was able to select a high-risk subgroup among patients with diabetes mellitus as well as non-diabetic patients, with 41% event rate in diabetic patients with BMIPP defect score 5 or more but only 4% event rate in non-diabetic patients with BMIPP defect score lower than 5.

One of the strength of BMIPP imaging in daily clinical use is its simplicity since it offers metabolic information without stress procedure. It is a matter of great interest whether rest‐ ing BMIPP imaging offers complementary or additional prognostic information to that pro‐ vided conventional stress perfusion imaging. One hundred and sity-seven consecutive patients with angina pectoris but without prior myocardial infarction who had undergone both BMIPP and stress thallium imaging were followed up for 48 months [99]. For overall cardiac events (5 hard and 29 soft events), multivariate Cox's analysis revealed that reduced BMIPP uptake, stress perfusion score, diabetes, and left ventricular ejection fraction were the significant predictors. No hard event was observed with normal BMIPP uptake, whereas 2 patients with nearly normal stress perfusion with impaired BMIPP uptake had a hard event. The authors concluded that resting BMIPP imaging may provide significant prognos‐ tic information independent of stress myocardial perfusion imaging.

Recently meta-analysis on the prognostic value of BMIPP imaging in acute coronary syn‐ drome, acute myocardial infarction, and stable coronary artery disease was reported [100]. In 3 studies involving 541 patients with suspected acute coronary syndrome who were excluded for acute myocardial infarction, an abnormal finding on BMIPP imaging significantly associated with future hard cardiac events, defined as cardiac death and non-fatal myocardial infarction. The negative predictive value of BMIPP imaging for fu‐ ture hard and soft events were 98.9% and 92.3% over 3.5 years, respectively. In 6 studies which comprised 607 patients with acute myocardial infarction, larger defect on BMIPP imaging was significantly associated with cardiac death and hard events with relative risk of 2.81 and 3.87, respectively. Two studies included 166 patients with stable coro‐ nary artery disease who underwent elective revascularization. Both studies evaluated the prognostic value of mismatched BMIPP uptake less than perfusion, and showed contrast‐ ing results depending on the timing of BMIPP imaging to relative to revascularization. The presence of mismatched myocardium before revascularization, which suggested a jeopardized but viable myocardium, is associated with fewer events if patients undergo successful revascularization. However, the mismatch occurs after revascularization, indi‐ cating residual ischemia, the more hard events occur.

#### **5.7. Chronic kidney disease**

nificant correlation was observed between the area with discordant FDG uptake more than sestamib and ejection fraction recovery [90]. The results are quite intuitive because, in ische‐ mic and viable myocardium, substrate shift from fatty acid to glucose would take place, hence, mismatch of FDG and BMIPP uptake should be prominent but mismatch between BMIPP and sestamibi might be modest. These data suggest that discordant BMIPP uptake less than perfusion may represent reversible ischemic myocardial injury or hibernating my‐ ocardium and that the regional and global dysfunction will improve after revascularization in patients with chronic stable coronary artery disease. Metabolic stunning is also a good marker of functional recovery. In acute myocardial infarction with emergency revasculariza‐ tion, BMIPP and tetrofosmin mismatch around 1 week after the revascularization predicted

Assessment of prognostic value of BMIPP imaging over perfusion tracers in patients with coronary artery disease is a matter of clinical importance. The initial study for the assess‐ ment of prognostic implications of BMIPP imaging was conducted in 50 consecutive pa‐ tients with myocardial infarction with a mean follow up period of 23 months [93]. During the follow-up period, 9 patients had cardiac events; 8 of the 9 patients with cardiac events showed discordant BMIPP uptake less than reinjection thallium, whereas only 20 of 41 pa‐ tients without cardiac events showed such mismatch. When all the clinical and radionuclide variables were analyzed by Cox regression analysis, presence of discordant BMIPP uptake was the best, and an independent, predictor of future cardiac events followed by the num‐ ber of coronary artery stenosis. BMIPP and thallium imaging performed within 1 month of acute myocardial infarction demonstrated that impaired BMIPP uptake and mismatched BMIPP uptake less than thallium are related to a high probability of fatal and non-fatal car‐ diac events [94] and the defect score of BMIPP and mismatched BMIPP uptake less than

thallium provided incremental predictive value for future cardiac events [95,96].

BMIPP uptake less than thallium may benefit from revascularization.

In the patients with chronic stage of myocardial infarction, clinical value of BMIPP imaging for predicting prognosis is also demonstrated. BMIPP imaging performed before revascula‐ rization in 76 patients with chronic stable ischemia (including 61 patients with myocardial infarction after at least 3 month of onset) with left ventricular dysfunction has been analyzed [97]. Patients with large amount of discordant BMIPP uptake less than thallium demonstrat‐ ed greater ejection fraction improvement after revascularization and, interestingly, showed significantly better event free survival than patients with small amount or no perfusion and metabolic mismatch. These data indicate that patients with significant amount of discordant

In chronic coronary artery disease without old myocardial infarction, value of BMIPP imag‐ ing for risk stratification has been also demonstrated. In 270 patients, BMIPP defect score was analyzed with respect to cardiac event during a median follow-up of 3.9 years [98]. Ka‐ plan-Meier survival estimates revealed that patients with a summed BMIPP defect score lower than 5 showed a better prognosis than the patients with more defect of BMIPP (a hard event-free survival rate at 3 years: 98% vs 93% (P = 0.03), all event-free survival rate at 3

recovery of ejection fraction and wall motion 3 month later [91,92].

**5.6. Risk stratification and prediction of the prognosis**

188 Ischemic Heart Disease

In chronic kidney disease (CKD), cardiovascular disease accounts for most of the morbid‐ ity and mortality in both pre-dialysis and after the onset of end stage renal disease. Stress myocardial perfusion imaging has become increasingly recognized as a powerful prognostic tool for cardiovascular outcomes in patents with known or suspected coro‐ nary artery disease. Abnormal stress myocardial perfusion scan is more common in pa‐ tients with CKD and stress perfusion imaging is confirmed as a powerful tool for predicting outcomes across entire spectrum of renal dysfunction. At the same time, pres‐ ence of CKD itself added prognostic value to perfusion imaging [101]. While stress per‐ fusion imaging is valuable method to assess coronary artery disease, stress test may not be suitable for substantial number of CKD patients, especially in end stage renal disease. Because an inability to exercise enough due to multiple comorbidity including obesity, arthritis, and deconditioning etc, and suboptimal vasodilator stress testing due to an in‐ complete vasodilator response due to endothelial dysfunction. In this context, BMIPP imaging can be performed safely and effectively at rest to detect metabolic alteration due to ischemia without stress testing.

**6. Summary and conclusions**

**Author details**

, Ichiro Matsunari2

2007 Jun;34 Suppl 1:S34-48.

Junichi Taki1

**References**

In normal condition approximately two-thirds or more of the total energy produced by my‐ ocardium is derived from fatty acid oxidation and myocardial substrates may change signif‐ icantly in various pathological conditions such as ischemia. Accordingly, many fatty acid tracers for SPECT imaging have been introduced. Until now, 123I-BMIPP, one of the methyl branched fatty acid analogues, is the only approved fatty acid tracer for daily clinical use. The concept of BMIPP imaging is metabolic trapping, like FDG, by inhibiting β-oxidation by introducing methyl branching at β-carbon position. Myocardial BMIPP uptake more likely reflects activation of BMIPP into BMIPP-CoA with consumption of ATP, thus the uptake in‐ directly reflects cellular ATP production by fatty acid metabolism. Under the condition of ischemia, the reduction of BMIPP uptake is observed by reflecting the reduction of ATP pro‐ duction due to depressed oxidative fatty acid metabolism and substrate shift from fatty acids to glucose. Reduced uptake of BMIPP at rest is often observed in ischemic myocardi‐ um independent of the uptake of perfusion tracers, that is, discordant or mismatched BMIPP uptake less than perfusion tracers. Through comparison with perfusion, BMIPP image can detect previous myocardial ischemia as an ischemic memory imaging (stunned myocardium or status of metabolic stunning) and viable but chronically dysfunctional myocardium (hi‐ bernating myocardium or status of metabolic remodeling). In addition, BMIPP image may offer incremental prognostic information in ischemic heart diseases. Through the basic and clinical studies, it has become clear that BMIPP imaging has a high potential utility in the entire spectrum of ischemic heart diseases in evaluating the patients with acute chest pain, acute myocardial infarction, unstable angina pectoris, chronic stable coronary artery diseas‐

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

es, in terms of diagnosis, risk stratification, and also for the prediction of prognosis.

, Hiroshi Wakabayashi1

1 Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan

[1] Taki J, Matsunari I. Metabolic imaging using SPECT. Eur J Nucl Med Mol Imaging.

[2] Tamaki N, Morita K, Kawai Y. The Japanese experience with metabolic imaging in

2 Medical & Pharmacological Research Center Foundation, Hakui, Japan

the clinical setting. J Nucl Cardiol. 2007;14(3 Suppl):S145-52.

, Anri Inaki1

and Seigo Kinuya1

http://dx.doi.org/10.5772/53548

191

In addition to the high prevalence of coronary artery disease in patients with CKD, several sequelae of renal failure also contribute to left ventricular metabolic remodeling, so-called uremic cardiomyopathy. In this condition, myocyte capillary mismatch, with diminished vascular supply relative to the number and volume of functioning myocytes is observed [102,103]. These epicardial and microvascular disorder should induce ischemia when car‐ diac demand increases. For the detection of coronary artery disease in asymptomatic pa‐ tients undergoing hemodialysis, dual isotope SPECT with thallium and BMIPP was investigated [104]. Significant coronary stenosis (>75%) was found in 72% of patients (93/130). When a BMIPP summed score of 6 or more was defined as abnormal, sensitivity, specificity, and accuracy for detecting coronary artery disease by BMIPP SPECT were 98.0%, 65.6%, and 90.0%, respectively. For the assessment of prognostic value of BMIPP in patients with hemodialysis, 318 asymptomatic patients without prior myocardial infarction under‐ went dual isotope SPECT with thallium and BMIPP [105]. During a mean follow up period of 3.6 ± 1.0 years, 50 died of cardiac event. Kaplan-Meier analysis showed that the cardiac death-free survival rates at 3 years were 61% and 98% in patients with BMIPP summed scores of >12 and <12, respectively. When the cutoff value of BMIPP–Tl mismatch score, a marker of ischemia, was determined to be 7, the sensitivity and specificity of BMIPP–Tl mis‐ match for predicting cardiac death were 86% and 88%, respectively. Kaplan-Meier survival estimates revealed that the event-free rates of cardiac death at 3 years were 53% in patients with BMIPP–Tl mismatch of > 7, whereas 96% in patients with BMIPP–Tl mismatch < 7. These finding suggested that significantly impaired myocardial fatty acid metabolism de‐ tected by BMIPP SPECT might predict the occurrence of cardiac death in asymptomatic he‐ modialysis patients. In addition, in patients with hemodialysis and complete coronary revascularization, BMIPP imaging abnormality and BMIPP thallium mismatch can also pre‐ dict cardiac death [106]. Further more, prospectively enrolled 155 patients receiving hemo‐ dialysis after angiography had confirmed the absence of obstructive coronary lesions were examined by BMIPP SPECT [107]. During a mean follow-up of 5.1 years, 42 patients died of cardiac events. Stepwise Cox hazard analysis demonstrated that cardiac death asscociated with reduced BMIPP uptake and increased insulin resistance. Thus, impaired myocardial fatty acid metabolism and insulin resistance may be associated with cardiac death among hemodialysis patients without obstructive coronary artery disease.

Accordingly, in patients with high risk CKD, BMIPP imaging at rest is highly valuable in terms of the assessment of the myocardial metabolic abnormality, stratifying the patient's risk, and predicting cardiac death.

## **6. Summary and conclusions**

ence of CKD itself added prognostic value to perfusion imaging [101]. While stress per‐ fusion imaging is valuable method to assess coronary artery disease, stress test may not be suitable for substantial number of CKD patients, especially in end stage renal disease. Because an inability to exercise enough due to multiple comorbidity including obesity, arthritis, and deconditioning etc, and suboptimal vasodilator stress testing due to an in‐ complete vasodilator response due to endothelial dysfunction. In this context, BMIPP imaging can be performed safely and effectively at rest to detect metabolic alteration due

In addition to the high prevalence of coronary artery disease in patients with CKD, several sequelae of renal failure also contribute to left ventricular metabolic remodeling, so-called uremic cardiomyopathy. In this condition, myocyte capillary mismatch, with diminished vascular supply relative to the number and volume of functioning myocytes is observed [102,103]. These epicardial and microvascular disorder should induce ischemia when car‐ diac demand increases. For the detection of coronary artery disease in asymptomatic pa‐ tients undergoing hemodialysis, dual isotope SPECT with thallium and BMIPP was investigated [104]. Significant coronary stenosis (>75%) was found in 72% of patients (93/130). When a BMIPP summed score of 6 or more was defined as abnormal, sensitivity, specificity, and accuracy for detecting coronary artery disease by BMIPP SPECT were 98.0%, 65.6%, and 90.0%, respectively. For the assessment of prognostic value of BMIPP in patients with hemodialysis, 318 asymptomatic patients without prior myocardial infarction under‐ went dual isotope SPECT with thallium and BMIPP [105]. During a mean follow up period of 3.6 ± 1.0 years, 50 died of cardiac event. Kaplan-Meier analysis showed that the cardiac death-free survival rates at 3 years were 61% and 98% in patients with BMIPP summed scores of >12 and <12, respectively. When the cutoff value of BMIPP–Tl mismatch score, a marker of ischemia, was determined to be 7, the sensitivity and specificity of BMIPP–Tl mis‐ match for predicting cardiac death were 86% and 88%, respectively. Kaplan-Meier survival estimates revealed that the event-free rates of cardiac death at 3 years were 53% in patients with BMIPP–Tl mismatch of > 7, whereas 96% in patients with BMIPP–Tl mismatch < 7. These finding suggested that significantly impaired myocardial fatty acid metabolism de‐ tected by BMIPP SPECT might predict the occurrence of cardiac death in asymptomatic he‐ modialysis patients. In addition, in patients with hemodialysis and complete coronary revascularization, BMIPP imaging abnormality and BMIPP thallium mismatch can also pre‐ dict cardiac death [106]. Further more, prospectively enrolled 155 patients receiving hemo‐ dialysis after angiography had confirmed the absence of obstructive coronary lesions were examined by BMIPP SPECT [107]. During a mean follow-up of 5.1 years, 42 patients died of cardiac events. Stepwise Cox hazard analysis demonstrated that cardiac death asscociated with reduced BMIPP uptake and increased insulin resistance. Thus, impaired myocardial fatty acid metabolism and insulin resistance may be associated with cardiac death among

hemodialysis patients without obstructive coronary artery disease.

risk, and predicting cardiac death.

Accordingly, in patients with high risk CKD, BMIPP imaging at rest is highly valuable in terms of the assessment of the myocardial metabolic abnormality, stratifying the patient's

to ischemia without stress testing.

190 Ischemic Heart Disease

In normal condition approximately two-thirds or more of the total energy produced by my‐ ocardium is derived from fatty acid oxidation and myocardial substrates may change signif‐ icantly in various pathological conditions such as ischemia. Accordingly, many fatty acid tracers for SPECT imaging have been introduced. Until now, 123I-BMIPP, one of the methyl branched fatty acid analogues, is the only approved fatty acid tracer for daily clinical use. The concept of BMIPP imaging is metabolic trapping, like FDG, by inhibiting β-oxidation by introducing methyl branching at β-carbon position. Myocardial BMIPP uptake more likely reflects activation of BMIPP into BMIPP-CoA with consumption of ATP, thus the uptake in‐ directly reflects cellular ATP production by fatty acid metabolism. Under the condition of ischemia, the reduction of BMIPP uptake is observed by reflecting the reduction of ATP pro‐ duction due to depressed oxidative fatty acid metabolism and substrate shift from fatty acids to glucose. Reduced uptake of BMIPP at rest is often observed in ischemic myocardi‐ um independent of the uptake of perfusion tracers, that is, discordant or mismatched BMIPP uptake less than perfusion tracers. Through comparison with perfusion, BMIPP image can detect previous myocardial ischemia as an ischemic memory imaging (stunned myocardium or status of metabolic stunning) and viable but chronically dysfunctional myocardium (hi‐ bernating myocardium or status of metabolic remodeling). In addition, BMIPP image may offer incremental prognostic information in ischemic heart diseases. Through the basic and clinical studies, it has become clear that BMIPP imaging has a high potential utility in the entire spectrum of ischemic heart diseases in evaluating the patients with acute chest pain, acute myocardial infarction, unstable angina pectoris, chronic stable coronary artery diseas‐ es, in terms of diagnosis, risk stratification, and also for the prediction of prognosis.

## **Author details**

Junichi Taki1 , Ichiro Matsunari2 , Hiroshi Wakabayashi1 , Anri Inaki1 and Seigo Kinuya1

1 Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan

2 Medical & Pharmacological Research Center Foundation, Hakui, Japan

## **References**


[3] Goodwin GW, Taegtmeyer H. Improved energy homeostasis of the heart in the meta‐ bolic state of exercise. Am J Physiol Heart Circ Physiol. 2000;279:H1490–H1501.

dial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

193

[17] Tanaka T, Nakata T, Oka T, Ogawa T, Okamoto F, Kusaka Y, et al. Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J Lipid

[18] Brinkmann JF, Abumrad NA, Ibrahimi A, van der Vusse GJ and Glatz JF. New in‐ sights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid

[19] Robinson GD, Jr. and Lee AW. Radioiodinated fatty acids for heart imaging: iodine monochloride addition compared with iodide replacement labeling. J Nucl Med

[20] Poe ND, Robinson GD, Jr., Graham LS and MacDonald NS. Experimental basis of myocardial imaging with 123I-labeled hexadecenoic acid. J Nucl Med

[21] Poe ND, Robinson GD, Jr., Zielinski FW, Cabeen WR, Jr., Smith JW and Gomes AS. Myocardial imaging with 123I-hexadecenoic acid. Radiology 1977;124:419-24

[22] Visser FC, van Eenige MJ, Westera G, Den Hollander W, Duwel CM, van der Wall EE, et al. Metabolic fate of radioiodinated heptadecanoic acid in the normal canine

[23] Freundlieb C, Hock A, Vyska K, Feinendegen LE, Machulla HJ and Stocklin G. Myo‐ cardial imaging and metabolic studies with [17-123I]iodoheptadecanoic acid. J Nucl

[24] Machulla HJ, Marsmann M and Dutschka K. Biochemical concept and synthesis of a radioiodinated phenylfatty acid for in vivo metabolic studies of the myocardium. Eur

[25] Reske SN, Sauer W, Machulla HJ and Winkler C. 15(p-[123I]Iodophenyl)pentadeca‐ noic acid as tracer of lipid metabolism: comparison with [1-14C]palmitic acid in mur‐

[26] Caldwell JH, Martin GV, Link JM, Krohn KA and Bassingthwaighte JB. Iodophenyl‐ pentadecanoic acid-myocardial blood flow relationship during maximal exercise

[27] Ercan M, Senekowitsch R, Bauer R, Reidel G, Kriegel H and Pabst HW. In vivo and in vitro studies with omega-[rho-123I-phenyl]-pentadecanoic acid in rats. Int J Appl Ra‐

[28] Rellas JS, Corbett JR, Kulkarni P, Morgan C, Devous MD, Sr., Buja LM, et al. Io‐ dine-123 phenylpentadecanoic acid: detection of acute myocardial infarction and in‐ jury in dogs using an iodinated fatty acid and single-photon emission tomography.

CD36 deficiency. Mol Cell Biochem 1999;192:129-35

translocase/CD36. Biochem J 2002;367:561-70

Res 2001;42:751-9

1975;16:17-21

1976;17:1077-82

heart. Circulation 1985;72:565-71

Med 1980;21:1043-50

J Nucl Med 1980;5:171-3

diat Isot 1983;34:1519-24

Am J Cardiol 1983;52:1326-32

ine tissues. J Nucl Med 1984;25:1335-42

with coronary occlusion. J Nucl Med 1990;31:99-105


dial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency. Mol Cell Biochem 1999;192:129-35

[17] Tanaka T, Nakata T, Oka T, Ogawa T, Okamoto F, Kusaka Y, et al. Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J Lipid Res 2001;42:751-9

[3] Goodwin GW, Taegtmeyer H. Improved energy homeostasis of the heart in the meta‐ bolic state of exercise. Am J Physiol Heart Circ Physiol. 2000;279:H1490–H1501.

[4] Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;

[5] Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic

[6] Camici P, Ferrannini E and Opie LH. Myocardial metabolism in ischemic heart dis‐ ease: basic principles and application to imaging by positron emission tomography.

[7] Lopaschuk GD, Collins-Nakai RL, Itoi T. Developmental changes in energy substrate

[8] Hwang EH, Yamashita A, Takemori H, Taki J, Nakajima K, Bunko H, et al. Absent

[9] Hashimoto J, Koseki S, Kinoshita F, Kubo A, Iwanaga S, Mitamura H, et al. Absent myocardial accumulation of two different radioiodinated pentadecanoic acids. Ann

[10] Tanaka T, Okamoto F, Sohmiya K and Kawamura K. Lack of myocardial iodine-123 15-(p-iodiphenyl)-3-R,S-methylpentadecanoic acid (BMIPP) uptake and CD36 abnor‐ mality--CD36 deficiency and hypertrophic cardiomyopathy. Jpn Circ J 1997;61:724-5

[11] Hwang EH, Taki J, Yasue S, Fujimoto M, Taniguchi M, Matsunari I, et al. Absent my‐ ocardial iodine-123-BMIPP uptake and platelet/monocyte CD36 deficiency. J Nucl

[12] Yoshizumi T, Nozaki S, Fukuchi K, Yamasaki K, Fukuchi T, Maruyama T, et al. Phar‐ macokinetics and metabolism of 123I-BMIPP fatty acid analog in healthy and CD36-

[13] Watanabe K, Ohta Y, Toba K, Ogawa Y, Hanawa H, Hirokawa Y, et al. Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 de‐

[14] Fukuchi K, Nozaki S, Yoshizumi T, Hasegawa S, Uehara T, Nakagawa T, et al. En‐ hanced myocardial glucose use in patients with a deficiency in long-chain fatty acid

[15] Kudoh T, Tamaki N, Magata Y, Konishi J, Nohara R, Iwasaki A, et al. Metabolism substrate with negative myocardial uptake of iodine-123-BMIPP. J Nucl Med

[16] Nozaki S, Tanaka T, Yamashita S, Sohmiya K, Yoshizumi T, Okamoto F, et al. CD36 mediates long-chain fatty acid transport in human myocardium: complete myocar‐

myocardial I-123 BMIPP uptake in a family. Ann Nucl Med 1996;10:445-8

use by the heart. Cardiovascular Research. 1992;26(12):1172–80.

278(4):H1345-51.

192 Ischemic Heart Disease

heart. Prog Cardiovasc Dis 1981;23:321-36

Prog Cardiovasc Dis 1989;32:217-38

Nucl Med 1998;12:43-6

Med 1998;39:1681-4

1997;38:548-53

deficient subjects. J Nucl Med 2000;41:1134-8

transport (CD36 deficiency). J Nucl Med 1999;40:239-43

ficiency. Ann Nucl Med 1998;12:261-6


[29] Garcia EV. Quantitative Nuclear Cardiology: we are almost there! J Nucl Cardiol. 2012 ;19(3):424-37.

dine-125-15-(p-iodophenyl)-3-(R,S)methylpentadecanoic acid (BMIPP), in relation to

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

195

[42] Nohara R, Okuda K, Ogino M, Hosokawa R, Tamaki N, Konishi J, et al. Evaluation of myocardial viability with iodine-123-BMIPP in a canine model. J Nucl Med

[43] Miller DD, Gill JB, Livni E, Elmaleh DR, Aretz T, Boucher CA, et al. Fatty acid ana‐ logue accumulation: a marker of myocyte viability in ischemic-reperfused myocardi‐

[44] Nishimura T, Sago M, Kihara K, Oka H, Shimonagata T, Katabuchi T, et al. Fatty acid myocardial imaging using 123I-beta-methyl-iodophenyl pentadecanoic acid (BMIPP): comparison of myocardial perfusion and fatty acid utilization in canine myocardial infarction (occlusion and reperfusion model). Eur J Nucl Med

[45] Noriyasu K, Mabuchi M, Kuge Y, Morita K, Tsukamoto T, Kohya T, et al. Serial changes in BMIPP uptake in relation to thallium uptake in the rat myocardium after

[46] Higuchi T, Taki J, Nakajima K, Kinuya S, Namura M and Tonami N. Time course of discordant BMIPP and thallium uptake after ischemia and reperfusion in a rat mod‐

[47] Naruse H, Arii T, Kondo T, Morita M, Ohyanagi M, Iwasaki T, et al. Clinical useful‐ ness of iodine 123-labeled fatty acid imaging in patients with acute myocardial in‐

[48] Mochizuki T, Murase K, Higashino H, Miyagawa M, Sugawara Y, Kikuchi T, et al. Ischemic "memory image" in acute myocardial infarction of 123I-BMIPP after reper‐ fusion therapy: a comparison with 99mTc-pyrophosphate and 201Tl dual-isotope

[49] Tamaki N, Tadamura E, Kudoh T, Hattori N, Inubushi M and Konishi J. Recent ad‐ vances in nuclear cardiology in the study of coronary artery disease. Ann Nucl Med

[50] Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram MY, Goodbody AE, et al. Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 2005;112:2169-74 [51] Tamaki N, Kawamoto M, Yonekura Y, Fujibayashi Y, Takahashi N, Konishi J, et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinat‐

[52] Franken PR, De Geeter F, Dendale P, Demoor D, Block P and Bossuyt A. Abnormal free fatty acid uptake in subacute myocardial infarction after coronary thrombolysis: correlation with wall motion and inotropic reserve. J Nucl Med 1994;35:1758-65

ischaemia. Eur J Nucl Med Mol Imaging 2003;30:1644-50

ed branched fatty acid analog. J Nucl Med 1992;33:659-67

ATP concentration. J Nucl Med 1990;31:1818-22

1996;37:1403-7

1989;15:341-5

1997;11:55-66

um. Circ Res 1988;63:681-92

el. J Nucl Med 2005;46:172-5

farction. J Nucl Cardiol 1998;5:275-84

SPECT. Ann Nucl Med 2002;16:563-8


dine-125-15-(p-iodophenyl)-3-(R,S)methylpentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med 1990;31:1818-22

[42] Nohara R, Okuda K, Ogino M, Hosokawa R, Tamaki N, Konishi J, et al. Evaluation of myocardial viability with iodine-123-BMIPP in a canine model. J Nucl Med 1996;37:1403-7

[29] Garcia EV. Quantitative Nuclear Cardiology: we are almost there! J Nucl Cardiol.

[30] Goodman MM, Kirsch G and Knapp FF, Jr. Synthesis and evaluation of radioiodinat‐ ed terminal p-iodophenyl-substituted alpha- and beta-methyl-branched fatty acids. J

[31] Knapp FF, Jr., Ambrose KR and Goodman MM. New radioiodinated methylbranched fatty acids for cardiac studies. Eur J Nucl Med 1986;12 Suppl:S39-44

[32] Sloof GW, Visser FC, van Lingen A, Bax JJ, Eersels J, Teule GJ, et al. Evaluation of heart-to-organ ratios of 123I-BMIPP and the dimethyl-substituted 123I-DMIPP fatty

[33] Ambrose KR, Owen BA, Goodman MM and Knapp FF, Jr. Evaluation of the metabo‐ lism in rat hearts of two new radioiodinated 3-methyl-branched fatty acid myocar‐

[34] Fujibayashi Y, Nohara R, Hosokawa R, Okuda K, Yonekura Y, Tamaki N, et al. Me‐ tabolism and kinetics of iodine-123-BMIPP in canine myocardium. J Nucl Med

[35] Hosokawa R, Nohara R, Fujibayashi Y, Okuda K, Ogino M, Hata T, et al. Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and re‐

[36] Hosokawa R, Nohara R, Fujibayashi Y, Okuda K, Ogino M, Hata T, et al. Metabolic fate of iodine-123-BMIPP in canine myocardium after administration of etomoxir. J

[37] Matsunari I, Saga T, Taki J, Akashi Y, Hirai J, Wakasugi T, et al. Kinetics of io‐ dine-123-BMIPP in patients with prior myocardial infarction: assessment with dy‐ namic rest and stress images compared with stress thallium-201 SPECT. J Nucl Med

[38] Kobayashi H, Kusakabe K, Momose M, Okawa T, Inoue S, Iguchi N, et al. Evaluation of myocardial perfusion and fatty acid uptake using a single injection of iodine-123- BMIPP in patients with acute coronary syndromes. J Nucl Med 1998;39:1117-22

[39] Fox KA, Abendschein DR, Ambos HD, Sobel BE and Bergmann SR. Efflux of metabo‐ lized and nonmetabolized fatty acid from canine myocardium. Implications for

[40] Duwel CM, Visser FC, van Eenige MJ and Roos JP. Variables of myocardial backdif‐ fusion, determined with 17-iodo-131 heptadecanoic acid in the normal dog heart.

[41] Fujibayashi Y, Yonekura Y, Takemura Y, Wada K, Matsumoto K, Tamaki N, et al. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, io‐

quantifying myocardial metabolism tomographically. Circ Res 1985;57:232-43

perfusion: implications for clinical SPECT. J Nucl Med 1997;38:1857-63

acid analogue in humans. Nucl Med Commun 1997;18:1065-70

dial imaging agents. Eur J Nucl Med 1987;12:486-91

2012 ;19(3):424-37.

194 Ischemic Heart Disease

1996;37:757-61

1994;35:1279-85

Nucl Med 1996;37:1836-40

Mol Cell Biochem 1989;88:191-4

Med Chem 1984;27:390-7


[53] Ito T, Tanouchi J, Kato J, Morioka T, Nishino M, Iwai K, et al. Recovery of impaired left ventricular function in patients with acute myocardial infarction is predicted by the discordance in defect size on 123I-BMIPP and 201Tl SPET images. Eur J Nucl Med 1996;23:917-23

um: comparison with thallium redistribution and glucose metabolism. Ann Nucl

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

197

[64] Kawai Y, Tsukamoto E, Nozaki Y, Morita K, Sakurai M and Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with

[65] Kontos MC, Dilsizian V, Weiland F, DePuey G, Mahmarian JJ, Iskandrian AE, et al. Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emer‐ gency department patients with suspected acute coronary syndromes: a multicenter

[66] Tateno M, Tamaki N, Yukihiro M, Kudoh T, Hattori N, Tadamura E, et al. Assess‐ ment of fatty acid uptake in ischemic heart disease without myocardial infarction. J

[67] Suzuki A, Takada Y, Nagasaka M, Kato R, Watanabe T, Shimokata K, et al. Compari‐ son of resting beta-methyl-iodophenyl pentadecanoic acid (BMIPP) and thallium-201 tomography using quantitative polar maps in patients with unstable angina. Jpn Circ

[68] Takeishi Y, Fujiwara S, Atsumi H, Takahashi K, Sukekawa H and Tomoike H. Io‐ dine-123-BMIPP imaging in unstable angina: a guide for interventional strategy. J

[69] Takeishi Y, Sukekawa H, Saito H, Nishimura S, Shibu T, Sasaki Y, et al. Impaired my‐ ocardial fatty acid metabolism detected by 123I-BMIPP in patients with unstable an‐ gina pectoris: comparison with perfusion imaging by 99mTc-sestamibi. Ann Nucl

[70] Taki J, Nakajima K, Matsunari I, Bunko H, Takada S and Tonami N. Impairment of regional fatty acid uptake in relation to wall motion and thallium-201 uptake in is‐ chaemic but viable myocardium: assessment with iodine-123-labelled beta-methyl-

[71] Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T, et al. Impaired fatty acid uptake in ischemic but viable myocardium identified by thallium-201 reinjec‐

[72] Tamaki N, Ohtani H, Yonekura Y, Nohara R, Kambara H, Kawai C, et al. Significance of fill-in after thallium-201 reinjection following delayed imaging: comparison with

[73] Ohtani H, Tamaki N, Yonekura Y, Mohiuddin IH, Hirata K, Ban T, et al. Value of thallium-201 reinjection after delayed SPECT imaging for predicting reversible ische‐

[74] He ZX, Shi RF, Wu YJ, Tian YQ, Liu XJ, Wang SW, et al. Direct imaging of exerciseinduced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m-ses‐

regional wall motion and angiographic findings. J Nucl Med 1990;31:1617-23

mia after coronary artery bypass grafting. Am J Cardiol 1990;66:394-9

tamibi in coronary artery disease. Circulation. 2003 ;108(10):1208-13.

acute chest pain. J Am Coll Cardiol 2001;38:1888-94

branched fatty acid. Eur J Nucl Med 1995;22:1385-92

trial. J Am Coll Cardiol. 2010 ;56(4):290-9.

Nucl Med 1996;37:1981-5

Nucl Med 1997;38:1407-11

tion. Am Heart J 1996;131:458-65

Med 1995;9:125-30

J 1997;61:133-8

Med 1994;8:47-54


um: comparison with thallium redistribution and glucose metabolism. Ann Nucl Med 1994;8:47-54

[64] Kawai Y, Tsukamoto E, Nozaki Y, Morita K, Sakurai M and Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 2001;38:1888-94

[53] Ito T, Tanouchi J, Kato J, Morioka T, Nishino M, Iwai K, et al. Recovery of impaired left ventricular function in patients with acute myocardial infarction is predicted by the discordance in defect size on 123I-BMIPP and 201Tl SPET images. Eur J Nucl

[54] Hashimoto A, Nakata T, Tsuchihashi K, Tanaka S, Fujimori K and Iimura O. Posti‐ schemic functional recovery and BMIPP uptake after primary percutaneous translu‐ minal coronary angioplasty in acute myocardial infarction. Am J Cardiol

[55] Franken PR, Dendale P, De Geeter F, Demoor D, Bossuyt A and Block P. Prediction of functional outcome after myocardial infarction using BMIPP and sestamibi scintig‐

[56] Nishimura T, Nishimura S, Kajiya T, Sugihara H, Kitahara K, Imai K, et al. Prediction of functional recovery and prognosis in patients with acute myocardial infarction by 123I-BMIPP and 201Tl myocardial single photon emission computed tomography: a

[57] Hambye AS, Vervaet A, Dobbeleir A, Dendale P and Franken P. Prediction of func‐ tional outcome by quantification of sestamibi and BMIPP after acute myocardial in‐

[58] Katsunuma E, Kurokawa S, Takahashi M, Fukuda N, Kurosawa T and Izumi T. Use‐ fulness of BMIPP SPECT to evaluate myocardial viability, contractile reserve and cor‐ onary stenotic progression after reperfusion in acute myocardial infarction. Jpn Heart

[59] Seki H, Toyama T, Higuchi K, Kasama S, Ueda T, Seki R, et al. Prediction of function‐ al improvement of ischemic myocardium with (123I-BMIPP SPECT and 99mTc-tetro‐ fosmin SPECT imaging: a study of patients with large acute myocardial infarction

[60] Furutani Y, Shiigi T, Nakamura Y, Nakamura H, Harada M, Yamamoto T, et al. Quantification of area at risk in acute myocardial infarction by tomographic imaging.

[61] Kawai Y, Tsukamoto E, Nozaki Y, Kishino K, Kohya T and Tamaki N. Use of 123I-BMIPP single-photon emission tomography to estimate areas at risk following suc‐ cessful revascularization in patients with acute myocardial infarction. Eur J Nucl

[62] Fukushima Y, Toba M, Ishihara K, Mizumura S, Seino T, Tanaka K, et al. Usefulness of 201TlCl/ 123I-BMIPP dual-myocardial SPECT for patients with non-ST segment el‐

[63] Kawamoto M, Tamaki N, Yonekura Y, Tadamura E, Fujibayashi Y, Magata Y, et al. Combined study with I-123 fatty acid and thallium-201 to assess ischemic myocardi‐

and receiving revascularization therapy. Circ J 2005;69:311-9

evation myocardial infarction. Ann Nucl Med. 2008 ;22(5):363-9.

Med 1996;23:917-23

raphy. J Nucl Med 1996;37:718-22

multicenter trial. Ann Nucl Med 1998;12:237-48

farction. Eur J Nucl Med 2000;27:1494-500

1996;77:25-30

196 Ischemic Heart Disease

J 2001;42:435-49

J Nucl Med 1997;38:1875-82

Med 1998;25:1390-5


[75] Dou KF, Yang MF, Yang YJ, Jain D, He ZX. Myocardial 18F-FDG uptake after exer‐ cise-induced myocardial ischemia in patients with coronary artery disease. J Nucl Med. 2008 ;49(12):1986-91.

[87] Hambye AS, Dobbeleir AA, Vervaet AM, Van den Heuvel PA and Franken PR. BMIPP imaging to improve the value of sestamibi scintigraphy for predicting func‐ tional outcome in severe chronic ischemic left ventricular dysfunction. J Nucl Med

Role of Fatty Acid Imaging with 123I- β-methyl-p-<sup>123</sup>I-Iodophenyl-Pentadecanoic Acid (<sup>123</sup>I-BMIPP)...

http://dx.doi.org/10.5772/53548

199

[88] Kudoh T, Tadamura E, Tamaki N, Hattori N, Inubushi M, Kubo S, et al. Iodinated free fatty acid and 201T1 uptake in chronically hypoperfused myocardium: histologic

[89] Taki J, Nakajima K, Matsunari I, Bunko H, Takata S, Kawasuji M, et al. Assessment of improvement of myocardial fatty acid uptake and function after revascularization

[90] Sato H, Iwasaki T, Toyama T, Kaneko Y, Inoue T, Endo K, et al. Prediction of func‐ tional recovery after revascularization in coronary artery disease using (18)F-FDG

[91] Biswas SK, Sarai M, Toyama H, Yamada A, Motoyama S, Harigaya H, et al. (123)I-BMIPP and (99m)Tc-TF discordance on myocardial scintigraphy and it's correlation with functional recovery following acute myocardial infarction: role of conventional

[92] Biswas SK, Sarai M, Yamada A, Motoyama S, Harigaya H, Hara T, et al. Fatty acid metabolism and myocardial perfusion imaging for the evaluation of global left ven‐ tricular dysfunction following acute myocardial infarction: comparisons with echo‐

[93] Tamaki N, Tadamura E, Kudoh T, Hattori N, Yonekura Y, Nohara R, et al. Prognostic value of iodine-123 labelled BMIPP fatty acid analogue imaging in patients with my‐

[94] Nakata T, Kobayashi T, Tamaki N, Kobayashi H, Wakabayashi T, Shimoshige S, et al. Prognostic value of impaired myocardial fatty acid uptake in patients with acute my‐

[95] Nanasato M, Hirayama H, Ando A, Isobe S, Nonokawa M, Kinoshita Y, et al. Incre‐ mental predictive value of myocardial scintigraphy with 123I-BMIPP in patients with acute myocardial infarction treated with primary percutaneous coronary interven‐

[96] Fukushima Y, Toba M, Ishihara K, Mizumura S, Seino T, Tanaka K, et al. Usefulness of 201TlCl/ 123I-BMIPP dual-myocardial SPECT for patients with non-ST segment el‐

[97] Fukuzawa S, Ozawa S, Shimada K, Sugioka J and Inagaki M. Prognostic values of perfusion-metabolic mismatch in Tl-201 and BMIPP scintigraphic imaging in patients with chronic coronary artery disease and left ventricular dysfunction undergoing re‐

echocardiography. Int J Cardiovasc Imaging. 2009 ;25(8):765-75.

1999;40:1468-76

correlation study. J Nucl Med 2000;41:293-6

using iodine-123-BMIPP. J Nucl Med 1997;38:1503-10

and (123)I-BMIPP SPECT. Chest 2000;117:65-72

cardiography. Int J Cardiol. 2010;138(3):290-9.

ocardial infarction. Eur J Nucl Med 1996;23:272-9

ocardial infarction. Nucl Med Commun 2000;21:897-906

tion. Eur J Nucl Med Mol Imaging 2004;31:1512-21

vascularization. Ann Nucl Med 2002;16:109-15

evation myocardial infarction. Ann Nucl Med. 2008 ;22(5):363-9.


[87] Hambye AS, Dobbeleir AA, Vervaet AM, Van den Heuvel PA and Franken PR. BMIPP imaging to improve the value of sestamibi scintigraphy for predicting func‐ tional outcome in severe chronic ischemic left ventricular dysfunction. J Nucl Med 1999;40:1468-76

[75] Dou KF, Yang MF, Yang YJ, Jain D, He ZX. Myocardial 18F-FDG uptake after exer‐ cise-induced myocardial ischemia in patients with coronary artery disease. J Nucl

[76] Kim SJ, Peppas A, Hong SK, Yang G, Huang Y, Diaz G, et al. Persistent stunning in‐ duces myocardial hibernation and protection: flow/function and metabolic mecha‐

[77] Camici PG and Rimoldi OE. Myocardial blood flow in patients with hibernating my‐

[78] Gerber BL, Vanoverschelde JL, Bol A, Michel C, Labar D, Wijns W, et al. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ven‐ tricular ischemic dysfunction. Implications for the pathophysiology of chronic myo‐

[79] Kageyama H, Morita K, Katoh C, Tsukamoto T, Noriyasu K, Mabuchi M, et al. Re‐ duced 123I-BMIPP uptake implies decreased myocardial flow reserve in patients

[80] Inaba Y, Bergmann SR. Diagnostic accuracy of beta-methyl-p-[123I]-iodophenyl-pen‐ tadecanoic acid (BMIPP) imaging: a meta-analysis. J Nucl Cardiol. 2008 May-Jun;

[81] Heijenbrok-Kal MH, Fleischmann KE, Hunink MG. Stress echocardiography, stress single-photon-emission computed tomography and electron beam computed tomog‐ raphy for the assessment of coronary artery disease: a meta-analysis of diagnostic

[82] Udelson JE, Bonow RO and Dilsizian V. The historical and conceptual evolution of radionuclide assessment of myocardial viability. J Nucl Cardiol 2004;11:318-34

[83] Srinivasan G, Kitsiou AN, Bacharach SL, Bartlett ML, Miller-Davis C and Dilsizian V. [18F]fluorodeoxyglucose single photon emission computed tomography: can it re‐ place PET and thallium SPECT for the assessment of myocardial viability? Circula‐

[84] Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease:

[85] Tamaki N, Tadamura E, Kawamoto M, Magata Y, Yonekura Y, Fujibayashi Y, et al. Decreased uptake of iodinated branched fatty acid analog indicates metabolic altera‐

[86] Hambye AS, Vaerenberg MM, Dobbeleir AA, Van den Heuvel PA and Franken PR. Abnormal BMIPP uptake in chronically dysfunctional myocardial segments: correla‐ tion with contractile response to low-dose dobutamine. J Nucl Med 1998;39:1845-50

comparison of pooled data. J Am Coll Cardiol. 1997 ;30(6):1451-60

tions in ischemic myocardium. J Nucl Med 1995;36:1974-80

with chronic stable angina. Eur J Nucl Med Mol Imaging 2006;33:6-12

Med. 2008 ;49(12):1986-91.

198 Ischemic Heart Disease

nisms. Circ Res 2003;92:1233-9

15(3):345-52.

tion 1998;97:843-50

ocardium. Cardiovasc Res 2003;57:302-11

cardial hibernation. Circulation 1996;94:651-9

performance. Am Heart J. 2007 ;154(3):415-23


[98] Chikamori T, Fujita H, Nanasato M, Toba M and Nishimura T. Prognostic value of I-123 15-(p-iodophenyl)-3-(R,S) methylpentadecanoic acid myocardial imaging in pa‐ tients with known or suspected coronary artery disease. J Nucl Cardiol 2005;12:172-8

[99] Matsuki T, Tamaki N, Nakata T, Doi A, Takahashi H, Iwata M, et al. Prognostic value of fatty acid imaging in patients with angina pectoris without prior myocardial in‐ farction: comparison with stress thallium imaging. Eur J Nucl Med Mol Imaging

[100] Inaba Y, Bergmann SR. Prognostic value of myocardial metabolic imaging with BMIPP in the spectrum of coronary artery disease: a systematic review. J Nucl Cardi‐

[101] Hakeem A, Bhatti S, Trevino AR, Samad Z, Chang SM. Non-invasive risk assessment in patients with chronic kidney disease. J Nucl Cardiol. 2011 ;18(3):472-85

[102] Dilsizian V, Fink JC. Deleterious effect of altered myocardial fatty acid metabolism in

[103] Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney

[104] Nishimura M, Hashimoto T, Kobayashi H, Fukuda T, Okino K, Yamamoto N, et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease

[105] Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll

[106] Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, et al. Myocardial fatty acid imaging identifies a group of hemodialysis patients at high risk for cardiac death after coronary revascularization. Kidney Int. 2008 ;74(4):513-20.

[107] Nishimura M, Tsukamoto K, Tamaki N, Kikuchi K, Iwamoto N, Ono T. Risk stratifi‐ cation for cardiac death in hemodialysis patients without obstructive coronary artery

kidney disease. J Am Coll Cardiol. 2008 ;51(2):146-8

in hemodialysis patients. Kidney Int. 2004;66(2):811-9.

2004;31:1585-91

200 Ischemic Heart Disease

ol. 2010 ;17(1):61-70.

Int Suppl. 2003 ;63(84):S80-3

Cardiol. 2008;51(2):139-45.

disease. Kidney Int. 2011;79(3):363-71.

## *Edited by David C. Gaze*

Cardiovascular disease (CVD) is ranked as the leading cause of death world wide, responsible for 17.1 million deaths globally each year. Such numbers are often difficult to comprehend. A coronary even occurs every 25 seconds and CVD kills one person every 34 seconds. 35 people under 65 years of age die prematurely every day due to CVD. The incidence of CVD has declined in recent years due to a better understanding of the pathology, implementation of lipid lowering therapy, new drug regimens and advances in acute surgical intervention. The disease burden has a great financial impact on global healthcare systems and major economic consequences for world economies. This text reviews the epidemiology, development, risk factors, diagnosis and treatment of ischemic heart disease.

Ischemic Heart Disease

Ischemic Heart Disease

*Edited by David C. Gaze*

Photo by 3quarks / iStock